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Abstract 
Loss of the signalling protein XLαs in mice leads to a lean phenotype 
characterised by increased energy expenditure due to elevated sympathetic 
nervous system (SNS) stimulation of brown adipose tissue. XLαs is the 
protein produced from the Gnasxl transcript of the imprinted Gnas locus, and 
has a restricted expression pattern that includes a number of brain regions 
essential for SNS control of both energy expenditure and the cardiovascular 
system. However, it is unknown to what degree XLαs influences overall 
sympathetic tone, or how XLαs signalling in the brain causes these 
phenotypic changes.  
Using arterial cannulation, anaesthetised Gnasxl knockout mice had elevated 
blood pressure, shown to be caused by increased SNS stimulation by a 
greater blood pressure response to the sympatholytic reserpine in knockouts. 
Using electrocardiogram (ECG) telemetry, conscious Gnasxl knockout mice 
had elevated heart rate at night, as well as a significant heart rate response 
to both reserpine and the parasympatholytic atropine. This supported the 
previous results showing elevated SNS stimulation of the cardiovascular 
system, but paradoxically also suggested elevated parasympathetic 
stimulation. Therefore, autonomic control of the cardiovascular system was 
investigated in further detail by analysing heart rate variability (HRV). 
A number of HRV analyses were experimentally validated in wildtype mice. 
The most reliable method was the fast Fourier transform (FFT); high 
frequency (HF) power was used as a measure of parasympathetic activity, 
and low frequency (LF)/HF ratio was used as a measure of sympathetic 
activity. Gnasxl knockouts had a greater LF/HF response to reserpine, but an 
equivalent HF response to atropine, suggesting the mice had elevated SNS 
activity only. Additionally, knockouts had elevated LF/HF ratio at night, 
suggesting consistently elevated SNS output.  
Neuronal signalling pathways that may be deregulated in Gnasxl knockouts 
were investigated by injection of MTII and Exendin-4, agonists to the 
melanocortin 3/4 and GLP-1 receptors, respectively. Gnasxl knockouts had a 
hypersensitive heart rate response both to centrally injected MTII in 
anaesthetised mice and peripherally injected Exendin-4 in conscious mice. 
The hypersensitivity to Exendin-4 was investigated further by HRV analysis, 
which showed that Exendin-4 had no effect on the SNS, but caused a potent 
reduction in parasympathetic activity in both wildtypes and knockouts. 
Neuronal signalling changes in response to Exendin-4 were investigated by 
antibody staining for the early response gene c-fos. No significant differences 
were seen in overall numbers of activated neurones between wildtypes and 
knockouts in a number of brain regions including the nucleus of the solitary 
tract (NTS). Interestingly, neurones expressing XLαs showed no c-fos 
response to Exendin-4, except in the area postrema. 
In summary, loss of XLαs in mice resulted in elevated SNS stimulation of the 
cardiovascular system, as well as hypersensitivity to Exendin-4 that was 
unlikely to be caused by increased activation of XLαs-deficient neurones.  
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1 Introduction 
1.1 Obesity and cardiovascular disease 
Obesity is a major global health concern (Figure 1). According to the World 
Health Organisation (WHO), worldwide obesity has doubled since 1980 
(www.who.int). In 2008, more than 1.4 billion adults were overweight, and 
500 million were obese, which is more than 10% of the global adult 
population. This is caused by a global increase in high-energy foods and a 
decrease in physical activity. Obesity has a number of pathological 
consequences, including cardiovascular disease, diabetes, osteoarthritis and 
cancers; risk factors for these diseases increase with BMI. In fact, 
cardiovascular disease is the major cause of death worldwide, and was 
responsible for 30.5% of deaths in 2008.  
Alterations in energy balance often correlate with effects to the 
cardiovascular system. For example, obesity is strongly correlated with 
hypertension and other forms of cardiovascular disease (Hall et al., 2010). 
These changes are frequently associated with changes in autonomic control, 
(Matsumura et al., 2003; Balthasar, 2009), in particular to the sympathetic 
nervous system (SNS) (Malpas, 2010). Animal models are useful for 
studying physiological control of energy balance, in particular transgenic 
mouse models are being used more and more. Disturbances to both energy 
balance and the cardiovascular system are relevant to this project and 
correlations will be investigated in Chapter 3, followed by further investigation 
in later chapters into the cardiovascular system.  
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Figure 1.1. Prevalence of obesity worldwide.  
Countries of the world are colour coded to indicate percentage obesity of the 
population, defined as those individuals with a BMI greater than or equal to 
30 kg/m2. Data are from 2008 (taken from WHO website October 2012: 
www.who.int)  
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1.2 The autonomic nervous system 
The autonomic nervous system regulates animal physiology to maintain 
homeostasis of the body’s systems, including the cardiovascular system and 
energy balance. A number of inputs feed into the central nervous system 
(CNS) where they are integrated, and the CNS exerts control via the two 
branches of the autonomic nervous system, the sympathetic and 
parasympathetic branches. The sympathetic nervous system (SNS) has 
classically been associated with the “flight or fight” response, and gives a 
stimulatory outcome to many peripheral tissues, for example increasing 
blood pressure and heart rate. The parasympathetic nervous system (PNS) 
opposes the SNS, and generally depresses peripheral effectors, for example 
decreasing blood pressure and heart rate. However, unlike the classic view 
of only acting in extreme situations, the SNS and PNS are constantly 
regulating homeostasis (Malpas, 2010). 
1.2.1 Autonomic hierarchy 
The autonomic nervous system is tightly controlled by a number of key brain 
regions, and the hierarchy of CNS control has been investigated in detail. 
The nucleus of the solitary tract (NTS) in the medulla is the primary site for 
information coming into the brain, via visceral afferents that synapse onto 
second order neurones in the NTS (Figure 1.2A) (Andresen & Paton, 2011).  
 There are also a few areas in the brain where the blood brain barrier (BBB) 
is “leaky”, allowing hormones and other peripheral factors to cross. These 
are the circumventricular organs, and include the area postrema (AP) which 
lies alongside the NTS and the arcuate nucleus (ARC) in the hypothalamus. 
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These inputs provide constant updates concerning the homeostatic status of 
the body.  
There are a number of brain regions crucial for initiation and control of SNS 
output (Figure 1.2B). Of particular importance to controlling SNS activity, is 
the paraventricular nucleus of the hypothalamus (PVN), which acts as a 
controlling hub of SNS outflow (Card & Sved, 2011). The PVN is subject to 
tonic GABAergic inhibition; sensitivity of the PVN neurones to GABA has 
been associated with elevated SNS activity and chronic heart failure (Patel, 
2000; Zhang et al., 2002; Li & Patel, 2003). 
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Figure 1.2. Central control of the autonomic nervous system. 
(A) Diagram showing the main brain regions involved in receiving and 
integrating autonomic inputs, especially via the NTS. 
(B) Diagram showing the main brain regions involved in initiation and control 
of the autonomic nervous system. Of particular important for SNS control is 
the PVN, and for SNS control of the cardiovascular system the RVLM. The 
NTS is especially important for control of the PNS. 
Sizes and locations of brain regions are approximate. 
Abbreviations used: PVN, paraventricular nucleus of the hypothalamus; 
DMH, dorsomedial nucleus of the hypothalamus; LH, lateral hypothalamus; 
ARC, arcuate nucleus; Amy, amygdala; PAG, periaqueductal grey; NTS, 
nucleus of the solitary tract; Pit., pituitary; CVLM, caudal ventrolateral 
medulla; RVLM, rostral ventrolateral medulla; AP, area postrema; Amb, 
ambiguus nucleus; DVN, dorsal vagal nucleus; IML, intermediolateralis of the 
spinal cord. Modified from (Andresen & Paton, 2011; Card & Sved, 2011; 
Stern, 2011).  
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1.2.2 Cardiovascular control 
It is important for the body to be able to maintain blood pressure at a 
constant level despite, for example, changes in posture that cause a drop in 
pressure, and to maintain blood pressure during changes to cardiac output, 
such as during exercise. The demand for blood pressure elevation must be 
balanced against the destructive force of high pressure, and a  number of 
homeostatic mechanisms are involved that include both short- and long-term 
control. 
Blood pressure is determined by a combination of blood volume, force of 
contraction of the heart, and peripheral resistance. Blood pressure can be 
controlled by direct stimulation by the autonomic nervous system, for 
example of the heart or blood vessels, or by indirect signalling, for example 
control of the kidney by the renin-angiotensin system. 
Autonomic control of the heart occurs via the SNS and the PNS, which 
provide stimulatory and inhibitory inputs, respectively (Figure 1.3A). 
Autonomic control of the vasculature is mainly by the SNS, which causes 
constriction of the vessels to increase peripheral resistance thereby 
increasing blood pressure (Figure 1.3B). 
The major cause of short-term blood pressure control is mediated via the  
baroreflex (Dampney et al., 2002); this consists of stretch sensitive 
baroreceptors in the aortic arch and the carotid body, which relay blood 
pressure information to the brainstem, specifically via the NTS and 
ventrolateral medulla. The baroreflex, initiated by either a decrease or 
increase in blood pressure, will result in reflex changes to both sympathetic 
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and parasympathetic output depending on the response required. There are 
also short-term “feed-forward” mechanisms which can alter blood pressure 
control depending on more complex behavioural activity (Dampney et al., 
2002). For example, anticipation of exercise results in increased 
cardiovascular stimulation. 
Long-term blood pressure control depends largely upon the activity of the 
kidneys, with regards to retention of water and salt (Dampney et al., 2005). 
The kidney is controlled by direct stimulation by the SNS, as well as indirectly 
by hormones including angiotensin II and vasopressin. These stimulate 
retention of salt and water, resulting in increased blood volume and therefore 
increased blood pressure. Renal sympathetic nerve activity is known to be 
increased in hypertension (Esler & Kaye, 1998). A number of CNS regions 
are known to be important for long-term blood pressure control, especially 
the rostral ventrolateral medulla (RVLM), and the hypothalamic PVN 
(Dampney et al., 2005). There are also indications that the baroreflex can be 
involved in long-term blood pressure control (Thrasher, 2004).  
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Figure 1.3. Control of heart and blood vessels by peripheral autonomic 
stimulation. 
Diagram showing the main intracellular pathways involved in control of the 
cardiovascular system by sympathetic and parasympathetic innervation.  
(A) The heart is heavily regulated by both the SNS and PNS, which release 
norepinephrine (NE) and acetylcholine (ACh), respectively, from the nerve 
terminals.  
(B) The vasculature is heavily regulated by the SNS; NE increases 
contractility, thereby increasing peripheral resistance.  
Modified from (Wettschureck & Offermanns, 2005).  
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1.2.3 Thermogenesis 
Body heat is generated in mammals by basal metabolism, muscle activity 
(eg. shivering) and non-shivering thermogenesis. Non-shivering 
thermogenesis is especially important for maintenance of body temperature 
in small mammals (such as rodents), and in babies, and is mediated by 
brown adipose tissue (BAT). BAT has also been shown to be physiologically 
relevant in adults (Cypess et al., 2009; Virtanen et al., 2009), which means 
that control of thermogenesis might prove relevant to pharmacological 
control of energy expenditure in humans.  
A number of brain regions play crucial control in the regulation of 
thermogenesis, including the preoptic area (POA), the DMH and the PVN. 
The POA contains temperature-sensitive neurones, and receives input from 
peripheral sensory pathways (Dimicco & Zaretsky, 2007). The DMH and 
PVN control SNS outflow downstream of the POA. Of particular importance 
to the control of thermogenesis is the DMH; injection of bicuculline 
methiodide (BMI), a GABAA receptor antagonist, into the DMH results in 
greatly increased body temperature due to increased BAT thermogenesis 
(Zaretskaia et al., 2002).  
It is interesting to note that, although the PVN is classically thought of as a 
stimulator of SNS activity, Madden and Morrison recently showed that BMI 
injection into the PVN not only causes a reduction in body temperature, it 
reverses the increases to SNS stimulation of BAT by BMI injection into the 
DMH (Madden & Morrison, 2009). 
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1.3 Hypothalamic control of energy balance 
The hypothalamus was identified as a crucial part of the control of energy 
balance from early lesion experiments. Systematic lesions of the VMH, PVN 
and DMH resulted in obesity, whereas lesions to the LH resulted in 
hypophagia (Hetherington & Ranson, 1940; Brobeck et al., 1943; Brobeck, 
1946; Anand & Brobeck, 1951). This led to the proposal that the VMH 
functions as a “satiety centre”, and the LH as a “hunger centre” (Gao & 
Horvath, 2008), whereas the DMH and PVN have a role in control of energy 
expenditure. 
1.3.1 Leptin and melanocortins 
Studies with the obese mouse models ob/ob and db/db led to the discovery 
of the hormone leptin, and the leptin receptor which is highly expressed in 
the hypothalamus (Zhang et al., 1994). Leptin is an adipokine hormone 
released from white adipose tissue which signals the adipogenic status of the 
animal. The identification of leptin led to the discovery of downstream 
melanocortin signalling pathways in the hypothalamus.  
Leptin acts on two primary populations of neurones in the arcuate nucleus, 
which have opposite effects on feeding. These are neurones expressing pro-
opiomelanocortin (POMC), which are anorexigenic, and neurones expressing 
neuropeptide Y (NPY) and agouti-related protein (AgRP), which are 
orexigenic. POMC is a precursor for α-melanocyte stimulating hormones (α-
MSH), which is an endogenous agonist for the melanocortin 3 and 4 
receptors (MC3R and MC4R) (Adan et al., 1994), whereas AgRP is an 
endogenous antagonist for the MC3/4R (Ollmann et al., 1997).  
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POMC neurones in the Arc are activated by leptin, whereas NPY/AgRP 
neurones are inhibited by leptin; these are thought to be the primary central 
regulators of energy balance (Xu et al., 2011). Furthermore, NPY neurones 
inhibit POMC neurones via GABA. In this way, leptin causes a potent 
stimulation of the MC3/4R in the hypothalamus by stimulating the activatory 
POMC neurones and inhibiting the inhibitory NPY/AgRP neurones. MC3/4R 
neurones are expressed in the Arc, PVN, LH and DMH (Mountjoy et al., 
1994; Sahm et al., 1994), and activation of them results in reduced food 
intake, and elevated energy expenditure, as well as increased blood 
pressure and heart rate (Fan et al., 1997).  
1.3.2 MC4R control of energy balance 
The circuitry of the melanocortin neurones has been investigated in detail. 
For example, neuroanatomical characterisation using fluorescent reporters 
showed that NPY neurones release GABA onto POMC neurones (Cowley et 
al., 2001). It was also shown that the POMC and NPY neurones of the Arc 
project to a number of hypothalamic regions, including the PVN and the LH 
(Mountjoy et al., 1994).  
Balthasar et al. used a loxSTOPlox conditional knockin of the MC4R (the 
LoxTB mouse) to investigate the function of MC4R in specific nuclei. The 
LoxTB mice are functional knockouts of MC4R unless cre enzyme removes 
the STOP cassette. For example, using a Sim1-cre mouse line, Balthasar et 
al. re-introduced MC4R specifically into the PVN and amygdala of mice 
otherwise lacking MC4R (Balthasar et al., 2005).  
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Mice lacking MC4R are normally obese, with increased food intake and 
reduced energy expenditure. However, re-introduction of the MC4R 
specifically into the PVN reduced the food intake back to normal levels, but 
energy expenditure remained low. This demonstrated that MC4R control of 
food intake and energy expenditure diverges, and that it is the MC4R in the 
PVN that is responsible for controlling food intake.  
Another study used choline acetyl transferase (ChAT)-cre crossed to the lox-
STOP-lox MC4R mouse rescues MC4R in cholinergic neurones of the IML 
layer of the spinal cord as well as the DMV. A second line Phox2b-cre 
rescued MC4R expression in parasympathetic neurones. It was found that 
MC4R rescue in parasympathetic neurones had no significant effects on 
energy expenditure or body weight, and that MC4R rescue in cholinergic 
neurones increased metabolic rate, and improved glucose and insulin control 
(Rossi et al., 2011). Therefore, it is likely that MC4Rs in the IML regulate the 
liver responses to insulin, whereas MC4Rs expressed in the DMV might 
regulate insulin release. 
There is an interesting role for GABA in the hypothalamic circuitry control 
energy balance. Selective deletion of the vesicular GABA transporter 
(VGAT), which is required for GABA release, from NPY/AgRP neurones 
results in elevated energy expenditure, which would be expected by 
disinhibition of the POMC neurones. A recent study by Vong et al. used 
conditional knockin mice to investigate the specific deletion of leptin receptor 
in GABAergic versus Glutamatergic neurones. They found that loss of leptin 
receptor from GABAergic neurones resulted in severe obesity, whereas loss 
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from Glutamatergic neurones had little effect on energy balance (Vong et al., 
2011).  
The hindbrain also plays a significant role in the control of energy balance,  
particularly in the control of feeding. Particularly the NTS and DMV, which 
are involved in the satiety response to cholecystekinin (CCK) (Silver et al., 
1989), and requires input from the vagus (Smith et al., 1985).   
1.3.3 Cardiovascular control by leptin and melanocortins 
Stimulation of POMC neurones by leptin results in activation of the SNS in 
control of the cardiovascular system in addition to the control of energy 
expenditure as discussed earlier. Activation of MC3/4R, particularly in the 
PVN, increases sympathetic nerve stimulation of the cardiovascular system, 
resulting in elevated blood pressure (Li et al., 2012). It has also been shown 
that chronically increased circulating leptin can result in elevated blood 
pressure (Hall et al., 2010).  
1.4 The imprinted Gnas locus 
Gsα, the stimulatory g-protein alpha subunit, is a signalling protein that 
couples g-protein coupled receptors (GPCRs) to adenylate cyclase (AC) to 
produce the second messenger cAMP. Gsα is encoded by the mouse gene 
Gnas, which is part of the imprinted gene locus, also called Gnas. 
1.4.1 Genomic imprinting 
Genomic imprinting is a phenomenon which occurs in mammals that results 
in epigenetic silencing of a gene depending on whether it was maternally or 
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paternally inherited. Gene silencing typically occurs by germline DNA 
methylation of an imprinting control region, which constitutes a region of CpG 
motifs (often referred to as a CpG island). The methylation results in 
transcriptional silencing, which results in allele-specific silencing and 
produces parent-of-origin specific effects.  
A number of imprinted genes have been identified in the mouse (Figure 1.4), 
and many cause growth defects, or developmental or behavioural 
abnormalities, when mutated. A recent study using high throughput 
transcriptional sequencing has shown that there may be many more 
imprinted genes than previously suspected (Gregg et al., 2010). 
1.4.2 Gnas locus 
Gnasxl is part of the complex imprinted Gnas locus, which is highly 
conserved between mice and humans (Gnas in mice; GNAS in humans). 
Many different transcripts are produced from the locus, some encoding fully 
functioning proteins, some encoding truncated proteins, and some are non-
coding (Figure 1.5) (Weinstein et al., 2007). The two main proteins produced 
from the locus are Gsα and its splice variant XLαs. Gsα has long been known 
as the target of cholera toxin, and is essential for mediating normal cAMP 
signalling pathways, which are explained in further detail in a later section. 
1.4.3 GNAS mutations in humans 
Homozygous loss of Gsα is universally lethal, but heterozygous deletions or 
mutations cause a range of metabolic phenotypes in humans and mice  
(Weinstein et al., 2007). Heterozygous loss of Gsα in humans (from either the 
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maternal or paternal allele) results in Albright’s hereditary osteodystrophy 
(AHO) (Spiegel & Weinstein, 2004), which includes a number of 
developmental and neurobehavioural abnormalities. It is interesting to note 
that loss of Gsα specifically from the maternal allele results in a number of 
additional phenotypes, including severe obesity and multi-hormone 
resistance (Weinstein et al., 2001). These additional phenotypes are caused 
by the tissue-specific imprinting of Gsα, which is silenced from the paternal 
allele in a number of tissues, including the pituitary, thyroid and renal 
proximal tubules, and the PVN (Weinstein et al., 2001; Chen et al., 2009). 
1.4.4 Gnas mutations in mice 
Loss of Gsα has similar effects in mice as it does in humans. Loss of Gsα 
from the paternal allele in a Gnas exon 1 mutant has little effect in terms of 
metabolism, but the mice have a similar phenotype to the symptoms seen in 
human AHO patients, including subcutaneous ossification (Sakamoto et al., 
2009; Huso et al., 2011). Furthermore, loss of Gsα from the maternal allele 
results in severe obesity, as well as glucose intolerance and insulin 
resistance and hormone resistance (Chen et al., 2005).  
A knockout model for the second exon of Gnas has an interesting imprinted 
phenotypic effect. Inheritance of a Gnas exon 2 deletion from the maternal 
allele (E2 m-/p+) has similar effects to the Gsα-specific knockout for Gnas 
exon 1, including obesity, glucose intolerance and insulin resistance.  
However, inheritance of Gnas exon 2 deletion from the paternal allele (E2 
m+/p-) has a largely opposite phenotype to the maternal inherited mutation, 
which includes decreased adiposity, glucose tolerance and insulin sensitivity 
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(Yu et al., 2000). This is caused by loss of the paternally inherited Gnasxl  
transcript (Figure 1.5), and the phenotypic effects of paternal Gnasxl  
mutation are dominant over the heterozygous mutation of Gnas from the 
paternal allele. 
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Figure 1.4. Known imprinted genes in the mouse. 
A schematic of imprinted genes, grouped by location on the mouse 
chromosomes. The yellow blocks indicate regions of known imprinting 
phenotypes, and known genes are shown in blue (paternally expressed) and 
in red (maternally expressed). Taken from the MRC Harwell Mousebook 
(Williamson et al., 2012).  
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1.5 Gnasxl and its product XLαs 
1.5.1 Gnasxl is a splice variant of Gnas 
Gnasxl is a splice variant of Gnas, and encodes the extra-large variant of 
Gsα (XLαs) (Kehlenbach et al., 1994; Peters et al., 1999). Gnasxl has its own 
unique promoter and first exon, and splices onto the same downstream 
exons 2-12 as Gnas (Figure 1.5). Unlike Gsα which is expressed 
ubiquitously, XLαs has a restricted expression pattern that includes distinct 
populations of neurones in the brain as well as peripheral tissues, and is 
known to change throughout development (Krechowec et al., 2012).  
In adult mice XLαs is expressed in the adrenal medulla, the intermediate 
pituitary and a number of brain regions including the hypothalamus 
(paraventricular, dorsomedial, lateral, arcuate and suprachiasmatic nuclei 
and the amygdala) as well as the hindbrain (the nucleus of the solitary tract, 
the gigantocellular reticular nucleus, the hypoglossal, the locus coeruleus 
and the Raphe Pallidus), and in the ventral motor neurones of the spinal cord 
(Pasolli et al., 2000; Krechowec et al., 2012).  
The expression pattern changes slightly throughout developmental stages of 
a mouse. In neonates, there is no XLαs expression in the NTS or amygdala, 
but there is additional neonatal-specific expression in the laterodorsal 
tegmental nucleus (LDTg), as well as a number of peripheral tissues 
including the smooth muscle cells of blood vessel walls and the tongue.  
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Figure 1.5. The complex imprinted Gnas locus. 
(A) Diagram of the Gnas locus, showing the maternal (red) and paternal 
(blue) alleles, as well as the majority of the transcripts produced from the 
locus. Differential parent-of-origin methylation of the genomic alleles is 
shown as MMM, which results in silencing of that region of the locus. The 
arrows show which transcripts are transcribed from each allele; the dotted 
line for Gnas on the paternal allele indicates that it is silenced in a limited 
number of tissues, including the PVN. Alternative transcript splicing is shown, 
with coding (black) and non-coding (white) regions of exons. XLN1 is a 
neural-specific splice variant of XLαs. Modified from (Weinstein et al., 2007). 
(B) Diagram of the Gnas locus, showing the location of mutations in the 
various mouse models described. 
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1.5.2 Gnasxl knockout 
Maternal inheritance of a Gnasxl knockout has no phenotypic effects; 
paternal inheritance has a phenotype very similar to the paternally inherited 
E2 mutant, including elevated energy expenditure and reduced fat mass.  
The Gnasxl knockout phenotype has a shift from neonatal to adult stages, 
most likely due to the changing expression pattern of XLαs (Krechowec et 
al., 2012). The neonatal phenotype includes defective suckling, leanness, 
inertia, hypoglycaemia, hypoinsulinaemia, elevated cAMP in BAT and a high 
mortality rate (Plagge et al., 2004). The suckling defect is possibly due to an 
endogenous effect of XLαs expression in the tongue; XLαs expression in the 
tongue is lost in adulthood and so is this phenotype (Krechowec et al., 2012).  
The Gnasxl knockout phenotype has been studied in detail with respect to 
control of lipid deposition and metabolism; the mice have a lean phenotype 
with greatly reduced adiposity that is maintained from birth throughout life 
(Plagge et al., 2004; Xie et al., 2006).  
Adult mice lacking XLαs have elevated energy expenditure, glucose 
tolerance, insulin sensitivity and markers of elevated stimulation of lipolysis  
and lipid oxidation in adipose tissue. This includes elevated mRNA levels of 
uncoupling protein 1 (UCP1), PPARγ and CREB in brown adipose tissue 
(BAT) (Xie et al., 2006), which are markers of elevated SNS stimulation of 
BAT. Xie et al. also showed that Gnasxl knockouts have increased levels of 
excreted epinephrine and norepinephrine (NE) in urine, which suggests 
heightened SNS activity. 
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There is also evidence that the elevated lipolysis is not a cell autonomous 
effect in the adipose tissue. There was no difference in response to a β3-
adrenoceptor agonist, which stimulates BAT lipolysis directly, between 
wildtypes and knockouts (Xie et al., 2006). Therefore, the only possible cell-
autonomous effect would have to be caused by a developmental problem 
with the BAT in knockouts. However, this would have to be caused indirectly, 
because XLαs is expressed in the blood vessels supplying BAT in neonates , 
not the brown adipocytes themselves (Krechowec et al., 2012).  
However, expression of XLαs in the blood vessels is lost in adulthood, so it is 
unlikely that loss of XLαs could affect signalling in later life (Krechowec et al., 
2012). It doesn’t seem as if XLαs has any effect in humans, as AHO patients 
with paternally inherited GNAS mutations do not mirror the lean phenotype of 
Gnasxl knockout mice (Plagge et al., 2008).  
1.5.3 Gnasxl copy numbers 
An interesting recent development in the investigation of XLαs is a study by 
Fernandez-Rebollo et al. which uses a mouse model of disrupted imprinting 
of the Gnas locus to investigate this from a different perspective (Fernandez-
Rebollo et al., 2012). The mouse model in question has a deletion of the 
Nesp55 transcript of the Gnas locus, which results in loss of methylation of 
the Gnas locus (Frohlich et al., 2010). The Nesp55 transcript is encoded by 
the Nesp gene, and is responsible for maintaining the imprint marks of the 
Gnas locus, therefore loss of Nesp55 from the maternal allele results in it 
having the same imprint marks as the paternal allele. This results in 
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expression of Gnasxl from both alleles, as well as tissue-specific silencing of 
Gnas from both alleles.  
Fernandez-Rebollo et al. then crossed these mice with paternally inherited 
Gnasxl mutation, thereby resulting in loss of Gnasxl back to a single copy 
number. Therefore, the effect of Gnasxl copy number could be investigated 
in the context of the hypocalcaemia, subcutaneous oedema and neonatal 
lethality of mice lacking both copies of Gsα from imprinted tissues. It is 
interesting to note that increasing the copy number of Gnasxl in this way 
resulted in decreased suckling and hypoglycaemia.  
It is therefore very interesting that increasing Gnasxl copy number not only 
has a distinct phenotype, but that this phenotype has similar aspects to loss 
of Gnasxl (Plagge et al., 2004). Therefore, not only is XLαs signalling 
important for its phenotypic effects, but the level of signalling is also 
important, and too much XLαs signalling can cause similar effects as too little 
XLαs signalling.  
1.6 cAMP-regulated cell signalling 
Regulated exocytosis, for example in neurones, is highly dependent upon 
Ca2+ which stimulates fusion of synaptic vesicles with the presynaptic 
membrane, thereby releasing the contents of the vesicle (in the case of a 
neurone, this could be a neurotransmitter such as glutamate or GABA). In a 
neuron, depolarisation of the membrane opens voltage-dependent calcium 
channels, which allows influx of Ca2+ from the extracellular environment, 
causing vesicle fusion. However, there are a number of factors that can 
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influence this process, including cAMP which has major functions in 
controlling exocytosis (Seino & Shibasaki, 2005).  
cAMP is a second messenger that acts primarily via protein kinase A (PKA), 
but also has other effectors including Epac and cyclic nucleotide gated 
(CNG) channels.  
1.6.1 PKA signalling 
PKA is a protein kinase with diverse downstream targets that vary depending 
upon the cell type, but the primary effector is cAMP response element 
binding protein (CREB), which is a transcription factor activated by PKA 
which controls expression of genes under cAMP response element (CRE) 
transcription control. For example, SNS stimulation of BAT stimulates cAMP 
production, which activates PKA, which then activated CREB by 
phosphorylation. CREB then enters the nucleus of the cell, where it activates 
transcription of UCP1, which is required for BAT thermogenesis (Cannon & 
Nedergaard, 2004). A large number of genes contain the cAMP response 
element (CRE), and are therefore transcriptionally controlled by CREB, 
including neuropeptides, hormones and ion channels (for a review see  
(Lonze & Ginty, 2002)). 
1.6.2 Epac signalling 
Epac is a guanine nucleotide exchange factor (GEF) which is activated by 
cAMP and is expressed in a number of tissues, but particularly in brain and 
heart. There are a number of downstream effectors for Epac, involved in a 
number of cellular processes (Laurent et al., 2012), but effects on exocytosis 
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may be mediated by Rab3, via the g-proteins Rim and Piccolo (Ozaki et al., 
2000). However, Epac has a lower affinity for cAMP than PKA, so it might be 
that Epac functions in microdomains in close proximity to the exocytic 
machinery where cAMP might accumulate to high concentrations in 
response to activation (Seino & Shibasaki, 2005). 
1.6.3 Cyclic nucleotide gated channels 
CNG channels are found in many cell types, including brain and heart. They 
are non-selective cation channels that allow influx of Ca2+ and Na+ in 
response to cyclic nucleotide binding. There are many variants of CNG 
channels that bind different cyclic nucleotides, but some are known to 
respond to cAMP; activation of CNG channels causes depolarisation and 
therefore activation of neurones (Seino & Shibasaki, 2005). 
1.6.4 Adenylate cyclase 
cAMP is produced by adenylate cyclase from ATP. Adenylate cyclase is 
stimulated by the stimulatory g-protein alpha subunit (Gsα), and is inhibited 
by the inhibitory g-protein alpha subunit (Giα) (Wettschureck & Offermanns, 
2005). These are members of the family of heterotrimeric g-proteins, so 
called because they act as trimers of α, β and γ subunits. There are a 
number of variants of each, including four families of Gα subunits which are 
known to couple to specific downstream signalling partners, for examples Gi 
and Gsα couple to adenylate cyclase, while Gqα stimulates phospholipase C 
(PLC)-β. There are also 5 variants of β subunit and 12 γ subunits. The β and 
γ subunits, although encoded separately, bind together strongly (with the 
exception of β-5) and act as a single unit. The expression of g-protein 
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variants is diverse, and some are expressed only in specific tissues 
(Wettschureck & Offermanns, 2005).  
1.7 G-protein coupled receptors 
 Heterotrimeric g-proteins are regulated by the activity of g-protein coupled 
receptors (GPCRs), which are a large family of membrane proteins that all 
consist of 7 transmembrane loops. Under basal conditions, the α, β and γ 
subunits are bound in a heterotrimeric complex. Upon activation, the α 
subunit releases a bound GDP, and binds a GTP which causes a 
conformational change and the βγ subunits are released (Figure 1.6).The α 
and βγ subunits are then free to act on downstream signalling partners. 
The GPCRs are a diverse family of receptors, and have been found to 
respond to factors as diverse as light, smells, and a range of 
neurotransmitters and hormones (Wettschureck & Offermanns, 2005). There 
are many known GPCRs in mammals, and for a number of these the 
endogenous ligand is not known, which are dubbed orphan receptors. Table 
1.1 gives a list of many of the known GPCRs involved in cardiovascular 
and/or metabolic regulation, as well as the heterotrimeric g-protein(s) they 
are known to couple to.  
The final major player in control of cAMP signalling is cAMP-specific 
phosphodiesterase (PDE), which degrades cAMP; intracellular targeting of 
PDEs can produce cAMP signalling microdomains by limiting the diffusion of 
cAMP away from the site of production. 
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Figure 1.6. Gsα signalling. 
Diagram showing intracellular Gsα signalling to produce cAMP in response to 
agonist.  
(A) Before stimulation of the g-protein coupled receptor (GPCR) by an 
agonist, Gsα is bound to GDP and the heterotrimeric g-proteins (α, β and γ) 
are bound together in the inactive state.  
(B) Agonist binding to the GPCR induces a conformational change, which 
causes Gsα to release GDP and bind GTP, thus activating Gsα and causing it 
to release the βγ subunits.  
(C) GTP-bound Gsα migrates along the membrane and activates adenylate 
cyclase, stimulating it to produce cAMP from ATP. Additionally, some signals 
are mediated by the released βγ subunits via other targets.  
(D) Gsα hydrolyses GTP back to GDP, releasing phosphate and returning 
Gsα to the inactive state. 
(E) Continued activation of Gsα causes it to be redistributed to the cytoplasm, 
where it can no longer signal via AC. Hydrolysis of GTP allows Gsα to return 
to the plasma membrane for further signalling. 
Modified from (Wettschureck & Offermanns, 2005).  
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Table 1.1. Some known g-protein coupled receptors (GPCRs). 
A number of GPCRs known to be involved in energy balance and/or 
cardiovascular control. Both the endogenous agonist and heterotrimeric g-
protein signalling partner(s) are listed. Modified from (Wettschureck & 
Offermanns, 2005). 
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1.8 cAMP signalling by XLαs  
1.8.1 XLαs protein domains 
XLαs shares the main functional domains with Gsα, which are encoded by 
the shared exons 2-12 (Figure 1.5) (Klemke et al., 2000). Additionally the 
unique exon of Gsα, which encodes part of the βγ binding domain, has highly 
conserved regions in XLαs (Figure 1.7) (Klemke et al., 2000). Therefore, any 
potential differences in intracellular signalling between XLαs and Gsα are 
likely to be mediated by the N-terminal regions of the unique XLαs domain, 
be it by directly influencing binding partners, or by influencing intracellular 
localisation of XLαs.  
The XLαs domain contains a number of recognisable domains, including a 
cysteine-rich region important for XLαs tethering to the membrane, a proline-
rich region and other regions containing EPAA or AARA repeats (Klemke et 
al., 2000). Although the early study by Klemke et al. suggested that XLαs is 
incapable of normal coupling between GPCRs and adenylate cyclase 
(Klemke et al., 2000), a number of further in vitro studies have shown that 
XLαs is capable of coupling specific GPCRs, including β2-adrenoceptors 
(Bastepe et al., 2002; Kaya et al., 2009; Liu et al., 2011). 
  
Chapter 1: Introduction 
29 
 
 
Figure 1.7. Gsα and XLαs protein domains.  
Gsα and XLαs share the main signalling domain and regulatory regions of the 
C-terminal domain. Additionally, although coded separately, the βγ-binding 
domain is very similar between the two. However, XLαs has a large unique 
N-terminal domain, which includes a cysteine-rich region for membrane 
anchorage, a proline-rich region and regions of EPAA and AARA amino acid 
repeats. Modified from (Klemke et al., 2000). 
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1.8.2 XLαs provides sustained signalling  
Some minor differences have been discovered in signalling between XLαs 
and Gsα; for example, it has recently been shown that XLαs remains at the 
plasma membrane following activation, resulting in sustained signalling and a 
prolonged cAMP signal (Liu et al., 2011).  
Gsα is known to become internalised following activation; sustained 
stimulation causes it to become redistributed from the plasma membrane to 
the cytoplasm (Wedegaertner et al., 1996), which constitutes an important 
mechanism that limits activation of Gsα (Thiyagarajan et al., 2002; Makita et 
al., 2007). This is a reversible effect; loss of Gsα stimulation by removal of 
the GPCR agonist results in Gsα being trafficked back to the plasma 
membrane, ready for further signalling (Wedegaertner et al., 1996) (Figure 
1.6).  
The recent study by Liu et al. showed that XLαs remains localised at the 
plasma membrane after activation, whereas Gsα is trafficked away from the 
membrane (Liu et al., 2011). Liu et al. showed that XLαs is fully capable of 
coupling both parathyroid hormone receptor (PTHR) and β2-adrenergic 
receptor (β2-AR), and that stimulation of the PTHR resulted in a prolonged 
cAMP signal which was not seen after β2-AR stimulation. This shows that 
there are definite differences not only in cAMP signalling by Gsα and XLαs, 
but also that XLαs can respond differently to different GPCRs. Whether this 
is caused by differences in XLαs binding affinity to the GPCR, different 
methods of desensitising the cAMP response of the different GPCRs, or by 
some other mechanism remains unclear. 
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It is possible that the main function of the XLαs-specific N-terminal domain is 
for maintaining XLαs at the plasma membrane following activation; there is a 
cysteine-rich region known to be responsible for targeting XLαs to the 
membrane by palmitoylation (Pasolli et al., 2000). Therefore, it is possible 
that the effects of XLαs are caused by the dual effect of its expression in a 
particular population of neurones and its ability to cause extended activation 
of those neurones. For example, it might be that XLαs is expressed in 
GABAergic neurones in the hypothalamus, and is responsible for maintaining 
tonic GABA release onto PVN neurones. 
However, there is a caveat with all these in vitro techniques, because it is a 
necessarily artificial system, ie. the proteins involved had to be added 
exogenously and overexpressed at high levels. Therefore, any conclusions 
drawn from such studies must take into account the fact that these are not 
necessarily at physiological expression levels and that many of the specific 
signalling partners or regulatory mechanisms may be absent, and all this 
could therefore influence the signalling properties.  
It is possible that, while XLαs is capable of signalling via adenylate cyclase, 
its primary signalling partners in vivo constitute a different signalling pathway 
entirely, or that the cAMP signalling resulting from XLαs stimulation acts on 
specific downstream partners for example due to localisation in an 
intracellular microdomain.  
Finally, there is the possibility that XLαs is capable of coupling the same  
upstream and downstream signalling partners as Gsα, but its function in vivo 
is controlled by its expression pattern. This possibility is supported by the 
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highly restricted expression pattern of XLαs, as well as the changing 
phenotype between neonate and adulthood apparently caused by the 
changing expression pattern of XLαs  (Krechowec et al., 2012).  
1.8.3 Structural binding of Gsα 
No crystal structure of XLαs exists, but the structure of Gsα has been 
determined to high accuracy (Sunahara et al., 1997), and this is likely to 
reflect the structure of XLαs, excluding the bulky N-terminal XLαs domain.  In 
addition, studies have determined the structure of Gsα in the inactive (GDP-
bound) state and the mechanism of binding to the β2-adrenergic receptor 
(Figure 1.8A) (Chung et al., 2011), as well as in the active (GTP-bound) state 
and the mechanism of binding to adenylate cyclase (AC) (Figure 1.8B) 
(Tesmer et al., 1997). These structures of Gsα are therefore useful for 
visualising how the XLαs domain might function.  
From the crystal structures of Gsα binding both to active β2-adrenergic 
receptor and to adenylate cyclase, it is clear that the N-terminal domain is 
situated at or near the interface with the opposing protein (Figure 1.8). 
Therefore, the XLαs-specific domain would be well placed to influence 
binding. In particular, with respect to binding AC, there doesn’t appear to be 
any room for an additional bulky protein domain at the N-terminus i f the 
proteins are expected to bind (Figure 1.8B). This might suggest that XLαs is, 
in principle, capable of binding both receptor and AC, but the bulky XLαs 
domain prevents it from binding AC as efficiently as Gsα.  
An early mouse model of the Gnas locus is the oedematous-small (oed-sml) 
mutation, which constitutes a point mutation in exon 6 of Gnas/Gnasxl, 
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resulting in a Valine to Glutamate mutation (Cattanach et al., 2000).This has 
similar phenotypic effects to the E2 knockouts, including homozygous 
lethality. Maternally inherited oed-sml mutation is similar to E2 m-/p+, 
including subcutaneous oedema and increased fat mass; paternally inherited 
oed-sml mutation is similar to E2 m+/p-, including a lean phenotype and 
decreased fat mass. Therefore, this provides evidence that loss of the 
catalytic activity of XLαs is required for the Gnasxl knockout phenotype.  
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Figure 1.8. Gsα structure and binding. 
Details of Gsα binding, using crystal structures.  
(A) Binding of inactive GDP-bound Gsα heterotrimeric g-proteins to activated 
β2-adrenergic receptor. From this diagram it is clear that the bulky extra-
large N-terminal XLαs domain could interfere with binding to the βγ subunits 
or the β-adrenergic receptor. Modified from (Chung et al., 2011). 
(B) Binding of active GTP-bound Gsα to the intracellular domain of adenylate 
cyclase (AC). It is also clear in this diagram that the bulky XLαs domain could 
interfere with binding to AC. Modified from (Tesmer et al., 1997). 
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1.9 Neuronal signalling by Gsα and XLαs 
1.9.1 Neuronal-specific knockout of Gsα 
A number of tissue-specific knockouts have been used to investigate the role 
of Gsα mutations in various tissues. It has been shown that loss of Gsα in 
peripheral tissues, including the liver, pancreas and adipose tissue, does not 
recapitulate the parent-of-origin effects of Gsα mutation (Chen et al., 2011). 
However, loss of maternal Gsα specifically in the CNS causes the parent-of-
origin effects of Gsα mutation on glucose and energy homeostasis (Chen et 
al., 2009).  
The maternally inherited brain-specific Gsα knockout (mBrGsKO) exhibited 
obesity, caused by decreased energy expenditure with no change in food 
intake. The mice were found to have decreased SNS activity and lowered 
blood pressure and heart rate. They were also hyperinsulinaemic and 
glucose intolerant. The food intake and energy expenditure responses to the 
MC3/4R agonist MTII were also investigated; mBrGsKO mice had a blunted 
increase in energy expenditure compared to wildtypes, but there was no 
effect on food intake.  
It was also shown that expression levels of Gnas transcript was reduced in 
the PVN of mBrGsKO mice compared to paternal brain-specific knockout 
(pBrGsKO) mice, but not in other brain regions such as the hippocampus 
and NTS. These data suggest that the energy expenditure effects of 
mBrGsKO might be caused by loss of Gsα in the PVN, and therefore a loss 
of MC3/4R signalling in this nucleus, which indicates that MC3/4Rs couple 
via Gsα. 
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1.9.2 PVN-specific knockouts of Gsα 
More recently, Gsα was deleted specifically in neuronal populations in the 
PVN, by crossing floxed Gnas mice with Sim1-cre mice to produce offspring 
with maternally deleted Gsα in PVN neurones (mPVNGsKO) (Chen et al., 
2012). These mice also suffered from obesity and reduced energy 
expenditure, but it was far milder than in the mBrGsKO mice, which means 
that only some of the actions of Gsα mediating energy balance are caused 
via the PVN.  
Futhermore, Chen et al. showed that mPVNGsKO mice had elevated 
circulating insulin and triglycerides, but no changes were seen in the other 
serum chemistries investigated including fed and fasted glucose levels as 
well as leptin and free fatty acids. They also showed that the mPVNGsKO 
mice responded to cold exposure in the same way as wildtypes, but 
mBrGsKO mice had an impaired response, both in body temperature change 
and induction of UCP1 expression in BAT. This indicates that the alterations 
in thermogenesis caused by lack of Gsα in the brain are not caused by 
expression in the PVN.  
However, the mPVNGsKO mice were found to have comparable reductions 
in blood pressure and heart rate as were seen in the mBrGsKO mice, 
suggesting that the cardiovascular effects of loss of Gsα in the brain are 
caused specifically by loss of expression in the PVN (Chen et al., 2012).  
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1.9.3 Melanocortins signalling via Gsα 
Gsα couples the melanocortin 3 and 4 receptors (MC3/4R), which act in the 
CNS to decrease food intake and increase SNS activity and energy 
expenditure (Brito et al., 2007; Nogueiras et al., 2007). Mice lacking MC4R 
develop severe obesity, caused by increased food intake and decreased 
energy expenditure (Balthasar et al., 2005).  
Balthasar et al. showed that MC4R signalling in the PVN mediated 
specifically the food intake effects, with no effect to energy expenditure 
(Balthasar et al., 2005). This is especially interesting in light of the 
mPVNGsKO mouse, where loss of Gsα in the PVN has no effect on food 
intake and minimal effects on energy expenditure (Chen et al., 2012). 
However, the mPVNGsKO had decreased blood pressure and heart rate, 
similar to the BrGsKO, which suggests that the functions of Gsα in the PVN is 
in cardiovascular control. 
Therefore the effects of Gsα and MC4R in the PVN do not necessarily match 
entirely, so there remains the possibility of other signalling pathways being 
involved; Chen et al. suggest that MC4R may couple to Gq in the PVN to 
cause the food intake changes.  
1.10 Aims 
The aims of this PhD are to investigate the effects of XLαs on autonomic 
control, specifically autonomic control of the cardiovascular system in adult 
Gnasxl knockout mice. Chapter 2 provides detail of the methods used, 
including arterial cannulation in anaesthetised mice with ICV drug injection, 
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ECG and heart rate monitoring in conscious mice by telemetry, heart rate 
variability (HRV) analysis and immunohistochemistry.  
Chapter 3 will use blood pressure and heart rate monitoring, in anaesthetised 
and conscious animals, respectively. Autonomic control of the cardiovascular 
system in Gnasxl knockouts will also be investigated by cardiovascular 
responses to antagonists to the SNS and PNS.  
Chapter 4 will examine autonomic control of the cardiovascular system in 
further detail by HRV analysis. A number of HRV analyses will be tested and 
validated in wildtype mice, followed by an exploration of HRV changes in 
mice lacking XLαs.  
The aim of Chapter 5 is to investigate how loss of XLαs might impact on 
cardiovascular control by known neuropeptide signalling pathways, including 
GLP-1. This will be performed by ICV injections into anaesthetised mice and 
peripheral injections in conscious mice.  
In Chapter 6, the neural pathways involved in XLαs signalling will be 
investigated by immunohistochemistry staining of the early response gene c-
fos to an agonist of the neuronal GLP-1 signalling pathway. Furthermore, the 
involvement of XLαs-expressing neurones in the c-fos response will be 
investigated by immunofluorescence colocalisation. 
Chapter 7 aims to identify a correctly targeted embryonic stem (ES) cell 
clone using Southern blotting for a conditional Gnasxl knockout, which could 
be used in the future to probe the effects of targeted deletion of XLαs.  
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Finally, Chapter 8 will review all the results presented in this thesis, provide 
overall conclusions, and give a speculative discussion of broader 
applications of the results as well as possible further experiments.  
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2 Methods 
2.1 Buffers and solutions 
2.1.1 General 
PBS Phosphate buffered saline (PBS) was made using PBS 
tablets (Sigma), according to the manufacturer’s 
instructions. 
10X TBS 100 mM Tris pH 7.5; 150 mM NaCl in H2O. 
20X SSC 3 M NaCl; 300 mM sodium citrate; pH 7.0 in H2O. 
2.1.2 Histology 
4% PFA Paraformaldehyde (PFA) was dissolved 4 % (w/v) in 
PBS, heated to 50 °C and 1 M NaOH added dropwise 
until the PFA dissolved. 
DAB 3,3’-Diaminobenzidine (DAB; Sigma) was dissolved in 
PBS and sterile filtered. Just before use 0.1 % (v/v) H2O2 
and 0.5 % (w/v) nickel chloride (NiCl2) were added. 
PBS-TX 0.25 % (v/v) Triton X-100 (Sigma) in PBS. 
Blocking solution 10 % (v/v) normal serum and 0.25 % (v/v) Triton X-100 
(Sigma) in PBS. 
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2.1.3 Protein gels and Western blotting 
Protein lysis 
buffer 
25 mM NaPO4 pH 7.5; 25 mM NaF; 25 mM β-
glycerolphosphate; 100 mM NaCl; 5 mM EGTA; 0.5 % 
(w/v) deoxycholate; 0.5 % (w/v) NP-40; 0.1 % (w/v) SDS; 
0.01 % (w/v) sodium azide in H2O. 0.5 mM PMSF, 
protease inhibitor cocktail (Sigma), phosphatase inhibitor 
cocktail (PhosStop; Roche) added just before use. 
Resolving gel 10 % (v/v) acrylamide mix (29:1 acrylamide: 
bisacrylamide); 390 mM Tris pH 8.8; 0.1 % (w/v) SDS in 
H2O. For polymerisation 0.1 % APS and 0.04 % TEMED 
were added. 
Stacking gel 5 % (v/v) 29:1 acrylamide:bisacrylamide mix (Accugel; 
National Diagnostics); 100 mM Tris pH 6.8; 0.1 % (w/v) 
SDS (National Diagnostics) in H2O. For polymerisation 
0.1 % APS and 0.04 % TEMED were added. 
SDS-PAGE 
electrophoresis 
buffer 
25 mM Tris Base; 250 mM glycine; 0.1 % (w/v) SDS in 
H2O. 
Transfer buffer 25 mM Tris pH 8.3; 192 mM glycine; 20 % (v/v) MeOH in 
H2O. 
TBS-T 0.1 % (v/v) Tween20 in TBS. 
Blocking solution 0.1 % Tween20 (v/v) and 5 % (w/v) skimmed milk 
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powder in TBS. 
Stripping buffer 62.5 mM Tris pH 6.8 ; 100 mM β-mercaptoethanol; 2 % 
(w/v) SDS in H2O. 
2.1.4 Southern blotting 
Dig buffer 1 0.1 M maleic acid; 0.15 M NaCl; pH 7.5 in H2O. 
Dig buffer 3 0.1 M Tris pH 9.5; 0.1 M NaCl; 0.05 M MgCl2 in H2O. 
10X blocking 
reagent 
Blocking reagent (Roche) was dissolved 10 % (w/v) in 
Dig buffer 1. 
Hybridisation 
buffer 
5X SSC; 1X blocking reagent; 0.1 % (w/v) N-
Lauroylsarcosine; 0.02 % (w/v) SDS in H2O. 
Wash buffer 1 2X SSC and 0.1 % (w/v) SDS in H2O. 
Wash buffer 2 0.1X SSC and 0.1 % (w/v) SDS in H2O. 
NBT stock Nitro Blue Tetrazolium (NBT) dissolved 75 mg/ml in 70 % 
dimethylformamide. 
BCIP stock 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) dissolved 
50 mg/ml in 70 % dimethylformamide. 
NBT BCIP colour 
reagent 
45 µl NBT stock and 35 µl BCIP added to 10 ml Dig 
buffer 3. 
2.1.5 PCR and DNA electrophoresis 
DNA lysis buffer 100 mM Tris pH 8.5; 5 mM EDTA; 200 mM NaCl; 0.2 % 
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(w/v) SDS in H2O. 
TE 10 mM Tris pH 8.0 and 1 mM EDTA in H2O. 
TAE 40 mM Tris; 20 mM acetic acid; 1 mM EDTA in H2O. 
2.1.6 Injectables 
Sterile saline 0.9 % (w/v) NaCl in H2O, autoclaved. 
aCSF 127 mM NaCl; 1.8 mM KCl; 1.2 mM KH2PO4; 2.4 mM 
CaCl2; 1.3 mM MgSO4; 26 mM NaHCO3; 15 mM glucose 
in H2O, as from (Belle et al., 2009). Solution was 
oxygenated. 
2.2 Animals 
Mice were maintained on a 12 hour/12 hour light/dark cycle, with unlimited 
access to standard chow and water. All experiments were performed in 
accordance with Home Office animal use regulations.  
2.2.1 Gnasxl knockouts 
Gnasxl knockout mice were bred on a CD1 background. CD1 females  
(Charles River) were bred with male maternally inherited Gnasxl knockout 
(Gnasxlm-/p+) carriers to produce paternally inherited Gnasxl knockout 
(Gnasxlm+/p-) offspring. Offspring inherited the Gnasxl knockout allele 
according to standard Mendelian inheritance; half of offspring were wildtype, 
half were m+/p- knockouts. 
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2.2.2 Breeding survivors 
Gnasxl knockout mice have low survival at birth – 0 % on an inbred C57/BL6 
background, approximately 10 % on an outbred CD1 background (Plagge et 
al., 2004). Survivability can be improved by culling of excess wildtypes one 
or two days after birth; culling was carefully controlled to leave paired 
wildtype-knockout offspring of each gender. Post weaning the knockouts no 
longer suffer from lethality effects, and become healthy, if lean, adults (Xie et 
al., 2006). 
2.2.3 Tissues 
Tissues for Western blotting were rapidly dissected from mice culled by 
Schedule 1, placed on dry ice, and kept at -80 °C until use. For histology, 
adult mice were killed by transcardial perfusion: mice were terminally 
anaesthetised by pentobarbitone injection; following loss of paw-withdrawal 
reflex the chest cavity was opened by dissection, the right atrium of the heart 
cut, and the mouse was perfused with saline then 4 % PFA. The brain was 
then rapidly dissected and placed on 4 % PFA, and kept overnight at 4 °C on 
a rocker. The brains were then transferred to sterile 30 % sucrose solution to 
dehydrate the tissue. 
2.2.4 Genotyping 
Mice were genotyped by ear notches taken at weaning. Tissues were lysed 
by overnight incubation in DNA lysis buffer containing Proteinase K (100 
µg/ml; Sigma) at 55 °C. Samples were then diluted 1:20 into sterile Elga 
water and heat denatured (15 minutes at 95 °C). 3 µl was taken for a 30 µl 
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PCR reaction containing the following: 1X GoTaq green buffer (Promega), 
dNTPs (200 µM each; Sigma), Primer XLF10 (0.83 µM), Primer XLR5 (0.83 
µM), MgCl2 (1.5 mM; Promega), 0.2 µl GoTaq (1 unit; Promega).  The 
following PCR conditions were used, with 30 cycle of steps 2-4:  
1. Hot Start 95 °C for 2 minutes  
2. 45 seconds at 95 °C denaturing step  
3. 45 seconds at 56 °C annealing step  
4. 2 minutes at 72 °C elongation step  
5. 5-minute final elongation step at 72 °C 
Samples were run on a 2 % agarose gel for 40 minutes at 80 V, and 
visualised by Ethidium Bromide staining on a GelDock; knockouts were 
identified as having a double band. 
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Table 2.1. Primer sequences.  
The primers used for genotyping PCR and for making Southern blot probes 
are detailed, including the base sequences.  
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2.3 Drug injections 
All drugs for peripheral injection were made up in sterile 0.9 % saline, except 
for reserpine which was dissolved in 1 % acetic acid. They were injected at 
50 µl volume, diluted according to the bodyweight of the mouse. 
All drugs for intracranial injections were made up in aCSF, and injected at 1 
µl for ICV injections.  
2.4 Histology 
2.4.1 Fixing and cutting 
Tissues were embedded in OCT mounting medium (Thermo Scientific), 
sections were cut to 12 µm thickness on a Leica cryostat, placed on a 
Superfrost slide (Thermo Scientific) and kept at -80 °C until use.  
2.4.2 Immunohistochemistry 
2.4.2.1 Antibodies 
Rabbit anti-c-fos Ab5 (1:50,000; Calbiochem), and the goat anti-rabbit 
VectaStain kit (Vector Laboratories). 
2.4.2.2 Staining protocol 
Immunohistochemistry (IHC) was performed for the early-response gene c-
fos on 12 µm cryostat sections, using the Vectastain Elite® kit (Vector 
laboratories). Sections were removed from -80 °C storage, left for 10 minutes 
to warm up and air dry, then incubated with PBS for 5 minutes. Endogenous 
Chapter 2: Methods 
48 
 
peroxidise activity was then quenched by 5 minutes incubation with 0.3 % 
H2O2 in MeOH, followed by three 5-minute PBS washes.  
Sections were blocked for 1 hour at room temperature in blocking solution 
(PBS-TX with 10 % normal goat serum), followed by an overnight incubation 
at 4 °C of rabbit anti-c-fos diluted 1:50,000 in blocking solution. After three 5-
minute PBS washes, sections were incubated with biotinylated goat anti -
rabbit (VectaStain) diluted 1:200 in blocking solution, according to the 
manufacturer’s instructions. This was followed by three more 5-minute PBS 
washes, then incubation with the VectaStain Elite ABC reagent made up in 
PBS, according to the manufacturer’s instructions (streptavidin-HRP 
conjugates). 
After three more 5-minute PBS washes was the colour development step. In 
this case, DAB (Sigma) solution was used, containing 0.3 % H2O2 and 0.05 
% (w/v) nickel chloride to produce a purple-black precipitate in the presence 
of HRP. After washing with PBS and H2O, sections were dehydrated with an 
ethanol series, then cleared twice using HistoClear (National Diagnostics), 
and finally mounted with Eukitt (Fluka). 
2.4.2.3 Microscopy and imaging 
Brightfield images were taken using a Leica mz16 microscope. 
2.4.3 Immunofluorescence 
2.4.3.1 Antibodies 
The following antibodies were used: rabbit anti-c-fos (1:2000; Calbiochem), 
goat anti-XLαs M14 (1:200; Santa Cruz), donkey anti-rabbit AlexaFluor 488 
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(1:1000; Invitrogen), donkey anti-goat AlexaFluor 594 (1:1000; Invitrogen), 
and finally the nuclear stain DAPI (0.1 µg/ml; Invitrogen).  
2.4.3.2 Staining protocol 
Immunofluorescence (IF) was used to stain for the early-response gene c-
fos, and counter-stain for XLαs. As with the IHC, 12 µm cryostat sections 
were removed from -80 °C storage and left for 10 minutes at room 
temperature to warm up and dry out. Sections were incubated 5 minutes in 
PBS, then blocked for 1 hour at room temperature using blocking reagent 
(PBS-TX with 10 % normal Donkey serum).  
Sections were then incubated overnight at 4 °C with primary antibodies 
against c-fos and XLαs diluted in blocking solution. Three 15-minute PBS 
washes were followed by 1 hour incubation at room temperature with the 
secondary antibodies and DAPI diluted in blocking solution. After three final 
15-minute PBS washes, slides were mounted with Fluorogel (Electron 
Microscopy Sciences), air dried, sealed, and kept at 4 °C in the dark.  
2.4.3.3 Microscopy and imaging 
Epifluorescent images were taken using a Zeiss Axioskop 40 microscope 
with Axioskop Vision software. 
2.5 Southern blotting 
2.5.1 Lysates 
Samples were lysed in lysis buffer with Proteinase K (100 µg/ml; Sigma) 
overnight at 55 °C. The DNA was then purified by isopropanol extraction. 
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Briefly, DNA was precipitated by addition of equal volume (ie. 500 µl) of 
isopropanol and thorough mixing by inversion, followed by a 1-minute spin at 
12,000 rpm. The supernatant was removed, leaving the DNA pellet, which 
was cleaned twice by addition of ice cold 70 % EtOH, mixing, spinning, and 
removal of the supernatant, followed by drying at 37 °C to remove excess 
EtOH. 50 µl TE was then added, and left at 4 °C for at least a week to ensure 
complete dissolving of the DNA. 
2.5.2 Restriction digests 
20 µl of DNA sample was used in a 40 µl restriction digest with addition of 
the following: 4 µl 10X Fastdigest buffer (Fermetas), 15 µl H2O and 1 µl of 
restriction enzyme. The enzymes used were all Fastdigest ® enzymes  
(Fermentas), and included BglI, BglII and SpeI. Digests were left overnight at 
37 °C to ensure complete digestion of the DNA.  
2.5.3 Gel 
The full 40 µl restriction digest was loaded onto a 0.8 % TAE agarose gel, 
and run for approximately 18 hours at 40 V. 1kb (Invitrogen) and λHIII 
ladders were run alongside, and a photo was taken of the gel on a Geldoc 
with a fluorescent ruler to provide size references; DNA was visualised with 
ethidium bromide. 
2.5.4 Transfer 
The gel was washed for 15 minutes each in 0.25 M HCl, then in 0.5 M NaOH 
(twice) and finally in 1 M NH4COOH (twice). The blot was then set up, using 
paper towels to draw up 1 M NH4COOH through the gel, thereby transferring 
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the DNA onto an Amersham nylon Hybond membrane (GE Healthcare). The 
blot was left for 48 hours during which time the towels were changed 
regularly and the 1 M NH4COOH was kept topped up. After blotting, the 
positions of the wells were marked on the membrane, and the DNA was 
crosslinked using 1200 µjoules of UV light. 
2.5.5 Probe synthesis 
Southern blot probes were synthesised by PCR using DIG-labelled UTP 
(Roche). Details of the primers used can be found in Table 2.1, but the PCR 
reaction was the same in all cases. Into each 50 µl reaction the following was 
added: 1 µl plasmid DNA, 36.5 µl H2O, 5 µl 10X Dig Synth PCR buffer 
(Roche), 5 µl 10X Dig Synth dNTP mix (including DIG-UTP; Roche), 1 µl 
forward primer, 1 µl reverse primer, 0.5 µl polymerase (Roche). For the XL5’ 
probe, the following PCR conditions were used, with 30 cycles of steps 2-4:  
1. Hot Start 95 °C for 5 minutes  
2. 30 seconds at 95 °C denaturing step 
3. 30 seconds at 56 °C annealing step  
4. 2 minutes at 72 °C elongation step  
5. 2-minute final elongation step at 72 °C  
For the Neo probe, the following PCR conditions were used, with 30 cycles 
of steps 2-4:  
1. Hot Start 95 °C for 5 minutes 
2. 45 seconds at 95 °C denaturing step  
3. 45 seconds at 58 °C annealing step  
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4. 2 minutes at 72 °C elongation step  
5. 2-minute final elongation step at 72 °C 
The probes were cleaned up by running on a 1.7 % agarose gel, cut out on a 
transilluminator and purified from the gel using gel extraction columns 
(Qiagen). Briefly, the gel was dissolved in approximately 200 µl binding 
buffer per 100 mg of gel and incubated for 10 to 15 minutes at 55 °C until 
fully melted/dissolved. This was added to the spin column, left for 2 minutes 
at room temperature, and spun at 12,000 rpm for 1 minute. Flow-through 
was discarded and 500 µl wash solution added to the column before spinning 
again; flow-through was discarded again and the wash repeated, followed by 
a final spin. 60 µl pre-warmed elution buffer was added to the column, left for 
5 minutes at 55 °C and spun to elute the probe, followed by repeating the 
elution step to obtain maximal product. 
2.5.6 Probe hybridisation and staining 
Several probe reactions were performed and pooled into each 50 ml probe 
mix in hybridisation buffer to provide high levels of staining. The membrane 
was equilibriated in 5x SSC for 3 minutes, then incubated for 1 hour at 68 °C 
in hybridisation buffer as a pre-hybridisation step, then hybridised overnight 
at 68 °C with the probe on a shaking platform. After hybridisation, the 
membrane was washed twice for 5 minutes in Wash buffer 1 at room 
temperature, twice for 20 minutes in Wash buffer 2 at 68 °C, then 
equilibriated for a few minutes in Dig buffer 1 at room temperature .  
The membrane was blocked for 90 minutes at room temperature with Dig 
buffer 1 containing 1 % blocking reagent (Roche), followed by a 30-minute 
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incubation with alkaline phosphatase-linked sheep anti-Dig (Roche) diluted 
1:5000 in Dig buffer 1 with 1 % blocking reagent. The membrane was then 
washed twice for 15 minutes with Dig buffer 1, then equilibriated for a couple 
of minutes in Dig buffer 3, followed by overnight incubation with NBT BCIP 
colour reagent at room temperature; the colour reaction was stopped by 
incubation with PBS for a couple of minutes.  
2.6 Western blotting 
2.6.1 Protein extraction 
Adult interscapular BAT samples were homogenised in protein lysis buffer, 
then sonicated to disrupt DNA. Samples were kept on ice at all possible 
times during the protocol. Samples were spun for 10 minutes at 12,000 g at 4 
°C. Protein concentration was determined using a Pierce® BCA protein 
assay kit (Thermo Scientific), and samples were kept at -80 °C until use.  
2.6.2 Gel and transfer 
PAGE gels were made by overlaying a resolving gel with a short stacking 
gel. Both were made up according to the recipes shown earlier; the 10 % 
APS and TEMED were added quickly just before being poured into the gel 
cassettes, and the gel was overlaid with isobutanol. Following 
polymerisation, the isobutanol and excess acrylamide were washed off with 
H2O before addition of the next gel, or use for electrophoresis. 100 µg of 
each protein lysate was diluted to 10 µl with H2O, then diluted 1:1 with 2x 
Laemlli protein loading buffer (National diagnostics), before being heat 
denatured by incubating for 3 minutes at 95 °C then quickly placing on ice.  
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Samples were loaded onto the PAGE gel along with a coloured protein 
ladder (Fermentas), and empty wells were fi lled with 1x Laemlli protein 
loading buffer. The gel was run in SDS-PAGE electrophoresis buffer at 10 
mA until the samples reached the resolving gel, then run at 15 mA until the 
blue dye ran off the bottom of the gel. The gel was then blotted to an 
Amersham PVDF Hybond membrane (GE Healthcare) by electrotransfer, 30 
V overnight at room temperature, in transfer buffer. The position of the wells 
was marked with a pencil.  
2.6.3 Staining 
The membrane was incubated for 10 minutes at room temperature with TBS-
T before blocking for 1 hour at room temperature with blocking solution 
(TBS-T with 5 % (w/v) skimmed milk powder). The membrane was incubated 
overnight at 4 °C with rabbit anti-P-HSL against Ser563 (Cell Signalling 
Technology) diluted 1:250 in blocking solution, followed by three 12-minute 
TBS-T washes, then incubated for 1 hour at room temperature with goat anti-
rabbit HRP (Jackson Laboratories) diluted 1:10,000 in blocking solution. After 
three more 12-minute TBS-T washes, samples were detected using 
Amersham ECL plus detection kit (GE Healthcare).  
The detection reagent was made up according to the manufacturer’s 
instructions, then incubated on the membrane for 5 minutes before exposure 
for 6 hours on Kodak X-ray film (Sigma). The membrane was then stripped 
by incubation for 30 minutes at 50 °C in stripping buffer, before being 
washed twice for 10 minutes with large volumes of TBS-T. HSL was then 
immunostained in the same was as P-HSL, except that the primary antibody 
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used was rabbit anti-HSL (Cell Signalling Technology), and was incubated 
for 1 hour at room temperature diluted 1:1000 in blocking solution, and the 
membrane was only exposed to X-ray film for 10 seconds. 
2.7 Cannulations 
Adult male Gnasxl knockout mice and wildtype siblings were anaesthetised 
with an appropriate dose of urethane-chloralose administered ip in saline. 
Following injection of the anaesthetic, the mice were returned to the cage for 
3 minutes until they became unconscious; body temperature was 
immediately recorded by rectal probe before exposure to a heat source.  
Following the initial measurement, body temperature was monitored by rectal 
probe, and maintained at 37 ±0.5 °C by heat lamp. Following loss of the paw-
withdrawal and eye-blink reflexes, the trachea was intubated to facilitate 
breathing.  
The carotid artery was cannulated with stretched PP25 tubing filled with 
heparinised saline; blood pressure was measured by a pressure transducer 
connected to a Neurolog blood pressure amp. Raw blood pressure signal 
was split, so that raw blood pressure could be recorded, as well as a second 
signal that was AC coupled and amplified between 10 and 100 times 
depending on signal strength. Both raw and amplified blood pressure signals 
were digitised to PC using a CED 1401 interface (Cambridge Electronic 
Design, Cambridge, UK) and recorded on Spike2 at 5 kHz.  
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2.7.1 Heart beat detection from blood pressure signal 
Heart rate was annotated from the AC coupled amplified blood pressure 
signal using Wabp from the Physionet suite of programs (Goldberger et al., 
2000). Briefly, the signal was analysed at 1/10th sampling frequency (ie. 500 
Hz), and resampled to 125 Hz for optimal beat detection by Wabp. Annotated 
beats were then reverted to 10 times speed to give the actual heart rate.  
2.7.2 Intracerebroventricular injections 
Anaesthetised cannulated mice were placed i n a mouse-adapted stereotaxic 
frame. The head was clamped in a level position and a hole was drilled at an 
appropriate location for the site of injection. Injections were performed using 
an appropriately sized Hamilton syringe according to the following 
stereotaxic coordinates relative to bregma, as determined from the Paxinos 
and Franklin adult mouse stereotaxic atlas (Paxinos & Franklin, 2001): 
intracerebroventricular (ICV) injection (0.2 mm caudal, 1.0 mm lateral, 3.5 
mm vertical).  
All drugs were dissolved in aCSF, and injected in 1 µl volume for ICV 
injections; liquid was expelled gradually over 30 seconds, and the syringe 
elevated 2 minutes following injection. The syringe was kept in place above 
the injection site during recording, and at the end of the experiment 1 % (w/v) 
Chicago blue dye (Sigma) was injected at the same injection coordinates and 
in the same volume as the drug. The mouse was then decapitated and the 
brain removed and placed in 4 % PFA. Following overnight fixation, the brain 
was cut to 300 µm on a vibratome to confirm correctly targeted injection by 
the location of blue dye.  
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2.8 Telemetry 
Telemetry was used to record electrocardiogram (ECG) and locomotor 
activity from conscious freely moving mice. The transmitters used were ETA-
F20 transmitters from DSI (Data Sciences International, MN, USA); 
biopotential and locomotor activity were recorded. 
2.8.1 Telemetry surgery 
ECG telemeters were implanted subcutaneously into adult male Gnasxl  
knockout mice and wildtype siblings, under isoflurane anaesthesia (Figure 
2.1A). Appropriate areas of the mouse’s skin were shaved and painted with 
videne antiseptic, and mice were given pre-operative subcutaneous 
injections of the analgesic buprenorphine (Temgesic, 1.5 mg/kg; Reckitt 
Benckiser, Slough, UK), the antibiotic enrofloxacin (Baytril, 0.2 ml/kg; Bayer 
AG, Leverkusen, Germany) and the anti-inflammatory meloxicam (Metacam, 
100 µg/kg; Boehringer Ingelheim, Germany).  
Incisions in the skin were made using a scalpel, and blunt dissection was 
used to create a pocket in the loose skin of the flank. The body of the 
transmitter was placed subcutaneously along the flank, and the electrodes 
were stitched in place to record electrical activity of the heart; one on the 
right pectoral muscle, the other by the diaphragm on the left side. Incisions 
were closed using individual sutures of 4/0 polysorb, which were 
subsequently glued with surgical superglue (Vetbond) to resist being chewed 
out by the mouse.  
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Surgery was performed under aseptic conditions. Following surgery mice 
were isolated and kept warm and monitored for recovery from anaesthesia; 
recording was started a minimum of 5 days after surgery. 
2.8.2 ECG recording 
Following recovery from surgery, ECG and locomotor activity were  recorded 
(Figure 2.1B). Mice were housed individually, each above a DSI telemetry 
receiver pad, and kept at least a metre apart to prevent cross-talk of signals.  
The ECG signal is transmitted as a short range FM signal from the 
transmitter, which is picked up by the receiver pad, where the ECG signal is 
AC coupled. The receiver pad is connected via an Ethernet cable to a DSI 
data exchange matrix (DEM), which provides power for the pads. En route to 
the DEM is a signal output adaptor, which extracts the ECG signal to a BNC 
output cable, which is connected to the interface, a CED micro1401 
(Cambridge Electronic Design, Cambridge, UK). The signal is digitised by the 
CED interface, and recorded on a PC by Spike2 at 5 kHz.  
Locomotor activity signal is initiated at the level of the receiver pad, which 
produces a binary signal burst after movement of the transmitter exceeds a 
certain threshold level. The activity signal was extrac ted directly from the 
Ethernet cable by splicing the relevant pin of the Ethernet cable to a BNC 
cable which was connected to the CED interface, where it was digitised and 
recorded at 100 Hz. Spike2 recording was automated to record continuously 
24-hours a day.  
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Figure 2.1. ECG telemetry surgery and recording in mice.  
(A) ECG telemeters (DSI) were implanted subcutaneously in adult male mice 
under isoflurane anaesthesia.  
(B) Following recovery ECG and locomotor activity were recorded from 
conscious freely moving mice.  
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2.8.3 Beat detection  
A custom program was developed in Java script (Netbeans IDE) to annotate 
heart beats from ECG. The raw ECG signal was first cleaned up in Spike by 
the process of DCremove using a time constant of 20 ms. This subtracts the 
average of 10 ms either side from each data point, and has similar effects to 
a high pass filter.  
The beat detection program recognises beats as regions of high variability. 
Specifically, a small window of ECG (2048 data points, ie. approximately 0.4 
seconds) is analysed, and the data point with the highest standard deviation 
is considered (Figure 2.2). If the data point is above a threshold of 2 times 
the standard deviation of the data points in the window, it is annotated as a 
beat and 200 data points (ie. 0.04 s) either side are blanked. The program 
then tests the next point with the highest standard deviation, and continues 
until there are no more points above the threshold, before moving the 
window along and analysing further data points.  
For analysis of circadian heart rate changes beats of more than 1000 bpm or 
less than 400 bpm, which are assumed to be ectopic or misread beats, are 
excluded. Heart rate responses to drug injections and heart rate variability 
are analysed directly from the raw heart beat annotation files, which contain 
heart beats annotated to a high degree of accuracy (ie. to within the 
sampling rate of 0.2 ms).  
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Figure 2.2. Heart beat detection from ECG.  
The beat detection program recognises beats based on the most extreme 
points that lie outside 2 standard deviations from the mean, from a window of 
2048 data points (ie. ~0.4s). Shown is one “window”, with annotated beats 
shown as red bars, and the level of 2SD above and below the mean. 
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2.8.4 Heart rate variability 
All heart rate variability (HRV) analyses were performed using Kubios HRV 
program (Niskanen et al., 2004), except for Lomb transforms which were 
performed using the Lomb program from the Physionet suite (Goldberger et 
al., 2000). In all cases, heart rate traces were visually inspected for 3-minute 
sections of clean and stable heart rate, which were then used for a number 
of HRV analyses.  
The standard deviation of normal RR intervals (SDNN) was calculated as the 
standard deviation in ms of the 3-minute section of heart rate. The root mean 
square of successive differences (RMSSD) is calculated as the difference in 
ms between each successive RR interval, squared, averaged from the 3-
minute period, and then square rooted. Poincaré plots were produced as 
each RR interval plotted against the following RR interval; the standard 
deviation was calculated at 45° rotation of each axis, producing SD1 and 
SD2 values (Figure 4.2Ai for a typical Poincaré plot). 
Three different power spectral analyses were used. For fast Fourier 
transforms (FFTs) and autoregressive spectra, heart rate was resampled to 
20 Hz. FFTs were performed using Welch’s algorithm using 32-second 
windows with 50 % overlap. Autoregressive spectra were produced using a 
32-order model. Lomb periodograms were produced from raw heart beat 
annotations, using the default settings on the Physionet Lomb program. The 
low frequency (LF) and high frequency (HF) bands were defined as 0.15-1.0 
Hz and 1.0-5.0 Hz, respectively (see chapter 4 for validation). Raw HF power 
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was used as an indicator of parasympathetic activity, and LF/HF ratio was 
used as an indicator of sympathetic activity. 
For further details of HRV and validation of the various analyses used, see 
chapter 4. 
2.9 Statistics 
Excluding representative plots for illustrative purposes, all graphs show 
mean ± standard error of the mean (SEM). For comparing basal 
physiological parameters between wildtypes and knockouts (for example in 
Figure 3.8 Aii), unpaired t-tests were used. For all other statistical analyses, 
paired t-tests were used. In figures 3.2 A, 3.2 B, 3.3 C and 3.8 B the 
differences in response were tested by paired t-test between wildtypes and 
knockouts, to account for the strictly dose-matched anaesthesia used. In all 
other cases, the responses were analysed by paired t-test within each 
genotype; in this way the response of each mouse was essentially paired 
with itself, to take into account variability in starting values, which can mask 
any drug effect.  
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3 Autonomic control of the 
cardiovascular system in mice 
lacking XLαs 
3.1 Introduction 
The sympathetic nervous system (SNS) plays a major role in the control of 
energy balance and the cardiovascular system (Hall et al., 2010). Elevated 
sympathetic stimulation of adipose tissue activates lipolysis and, in brown 
adipose tissue (BAT), stimulates thermogenesis which results in increased 
metabolic rate (Cannon & Nedergaard, 2004).  
Elevated sympathetic stimulation of the cardiovascular system results in 
elevations to blood pressure and heart rate ; for example elevated blood 
pressure in the Schlager hypertensive mouse is caused by increased SNS 
activity (Davern et al., 2009). Chronic elevations to SNS activity have been 
identified as characteristic of a number of cardiovascular diseases, including 
chronic heart failure (Fisher et al., 2009). 
3.1.1 Elevated SNS in animal models 
Animal models in which there is a global increase in SNS activity, resulting in 
a lean animal with hypertension, include mice with artificial overexpression of 
leptin (Ogawa et al., 2002) or α-MSH (Savontaus et al., 2004), as well as 
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knockouts for the central nervous system renin-angiotensin system 
(Takahashi et al., 2011).  
Another mouse model of hypertension, the Schlager hypertensive mouse, is 
known to be caused by elevated SNS activity (Davern et al., 2009), but no 
metabolic changes have so far been reported. Interestingly, the brain renin-
angiotensin system contributes little to the hypertensive phenotype of the 
Schlager mouse (Palma-Rigo et al., 2011), so there are clearly multiple 
parallel system that control the SNS effects on the cardiovascular system.  
Mouse models can have more selective effects, for example increasing just 
cardiovascular SNS stimulation in the Schlager hypertensive mouse (Davern 
et al., 2009) or modifying energy expenditure without affecting the 
cardiovascular system (Tallam et al., 2005). It is therefore of interest to 
investigate effects to the cardiovascular system in lean Gnasxl knockout 
mice. 
3.1.2 The SNS in Gnasxl knockouts 
Adult mice lacking XLαs have elevated sympathetic stimulation of the brown 
and white adipose tissues, which results in increased metabolism (Xie et al., 
2006). However, the effects to the cardiovascular system are unknown, 
although it has been previously suggested that the mice have a global 
increase in SNS activity (Xie et al., 2006).  
The aim of this chapter is to investigate the cardiovascular phenotype of 
Gnasxl knockout mice, in particular investigating SNS control of the 
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cardiovascular system, as well as a brief investigation into the physiological 
effects of elevated SNS stimulation of the adipose tissue.  
The hypothesis, that Gnasxl knockout mice suffer from a global increase in 
SNS activity that causes hypermetabolism and hypertension, is strongly 
supported by the neuronal expression pattern of XLαs. This includes the 
PVN, DMH, Arc, Raphe pallidus and the NTS (Pasolli et al., 2000; Pasolli & 
Huttner, 2001; Krechowec et al., 2012). XLαs expression in these brain 
regions, especially the DMH and PVN which are critical for control of the 
SNS (Loewy, 1991; Coote, 2007; Dimicco & Zaretsky, 2007; Nunn et al., 
2011), mean it is well placed to be controlling global SNS activity.   
3.1.3 XLαs versus Gsα 
There is an interesting dichotomy between XLαs and its splice variant Gsα 
concerning control of metabolism and the cardiovascular system. The mRNA 
transcripts Gnasxl and Gnas, which encode the proteins XLαs and Gsα, 
respectively, are oppositely imprinted – Gnasxl is silenced on the maternal 
allele (Hayward et al., 1998; Peters et al., 1999; Plagge et al., 2004) while 
Gnas is silenced on the paternal allele, but only in certain cell types (Peters 
et al., 1999; Plagge et al., 2008; Chen et al., 2009).  
Mice lacking XLαs or Gsα have functionally opposite phenotypes; loss of 
XLαs results in a lean phenotype with hypermetabolism, glucose tolerance 
and insulin sensitivity (Xie et al., 2006), whereas loss of Gsα results in an 
obese phenotype with hypometabolism, glucose intolerance and insulin 
resistance (Chen et al., 2005). It therefore stands to reason that the 
signalling proteins function in an antagonistic manner, and that any further 
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phenotypic effects are likely to be opposite between the two genotypes. As 
more is known about the Gnas knockout, certain predictions can be made 
about the Gnasxl knockout.  
Firstly, it has been shown, using a tissue- and maternal allele-specific 
knockout of Gsα, that the metabolic effects of Gsα are caused specifically by 
loss of the signalling protein in the brain (Chen et al., 2009). Therefore, this 
might suggest that XLαs also functions in the brain to cause an opposite 
metabolic phenotype.  
Secondly, loss of Gsα in the brain results in a hypotensive phenotype, with 
reduced heart rate and a global decrease in SNS activity (Chen et al., 2009). 
Therefore, one might predict that loss of XLαs may result in hypertension, 
with increased heart rate and a global increase in SNS activity.  
Thirdly, the brain-specific Gnas knockout is resistant to an agonist to the 
melanocortin 3/4 receptors (MC3/4R) (Chen et al., 2009), which stimulate the 
SNS and energy expenditure (Haynes et al., 1999; Kuo et al., 2004; Tallam 
et al., 2005; Tallam et al., 2006; Corander et al., 2009; Rossi et al., 2011). 
Therefore, loss of XLαs might result in increased sensitivity to a melanocortin 
agonist.  
Finally, mice with Gsα conditionally mutated in the PVN retain the 
cardiovascular phenotype of maternal brain-specific Gsα knockouts, but not 
the metabolism effects (Chen et al., 2012). Therefore, the cardiovascular 
effects of XLαs deletion might be expected to be caused by loss of XLαs 
from the PVN. 
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3.1.4 Aims 
This chapter will investigate effects to the cardiovascular system in adult 
male Gnasxl knockout mice, focussing on indicators of sympathetic activity. 
This includes blood pressure monitoring in anaesthetised mice and heart rate 
monitoring in conscious mice, as well as injection of reserpine and atropine 
as antagonists to the autonomic control of the cardiovascular system. 
Additionally, body temperature control in Gnasxl knockouts will be briefly 
examined. 
3.2 Methods 
A number of approaches were used to investigate control of the 
cardiovascular system in Gnasxl knockout mice. All experiments were 
performed on adult male knockouts and wildtype siblings. The anaesthetic 
urethane was used for terminal anaesthetic recordings, as this is 
documented to have minimal cardiotropic effects compared to other  
injectable anaesthetics (Carruba et al., 1987; Janssen et al., 2004), and the 
dose was more tightly regulatable compared to inhalation anaesthetics.  
Additionally, α-chloralose was added to the urethane to provide improved 
anaesthesia at lower dosages of urethane (Dalkara et al., 1995; Kass et al., 
1998), and furthermore, the urethane-chloralose was strictly dose-matched 
within sibling groups to equalise any detrimental effects of the anaesthesia 
on the cardiovascular system.  
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The other technique used to record cardiovascular parameters was 
electrocardiogram (ECG) telemetry, from which heart rate and locomotor 
activity were recorded from conscious freely moving mice. 
In conjunction with the recording of cardiovascular parameters by 
cannulation and telemetry, reserpine was used to inhibit sympathetic activity, 
specifically SNS stimulation of the cardiovascular system.  
Reserpine inhibits the vesicular monoamine transporter, thereby inhibiting 
noradrenaline packaging into neurotransmitter vesicles in sympathetic nerve 
terminals giving a global reduction in sympathetic stimula tion of peripheral 
tissues (Carlsson et al., 1963; Iversen et al., 1965).  
Reserpine was therefore used as a “pure” sympatholytic, as it lacks the off-
target effects of other global sympatholytics such as hexamethonium, 
pentolinium, or clonidine, or the “narrow” effects of targeted sympatholytics 
such as propranolol or prazosin (Bakris & Frohlich, 1989). Reserpine was 
dissolved in 1 % acetic acid solution, and injected 2 mg/kg ip in 
anaesthetised mice and 1 mg/kg ip in conscious mice. 
Atropine was used as a classic parasympatholytic, to inhibit parasympathetic 
stimulation of the cardiovascular system (Katona & Jih, 1975), as an 
antagonist to the muscarinic acetylcholine receptor. It was injected at 2 
mg/kg ip in conscious mice. 
Further details of the methods used can be found in chapter 2. 
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3.3 Results 
3.3.1 Arterial cannulation in anaesthetised mice 
Cannulation was initially performed using urethane anaesthesia on adult 
male Gnasxl knockouts and wildtype siblings. However, there was high 
variability in recorded blood pressure, most likely due to the high and 
variable doses of urethane needed to achieve full anaesthesia, with the 
result that no significant differences were seen between knockouts and 
wildtypes (data not shown).  
The experiment was therefore repeated using a mixed anaesthetic of 
urethane and α-chloralose in strictly dose-matched sibling groups (Figure 3.1 
for representative data). 
3.3.1.1 Basal cardiovascular parameters in anaesthetised Gnasxl 
knockout mice 
Under urethane-chloralose anaesthesia, Gnasxl knockouts were found to 
have elevated blood pressure compared to dose-matched sibling wildtypes 
(Figure 3.2A; 62 ±5 vs 47 ±5 mmHg, KO vs WT, p≤0.05 by paired t-test, 
n=8), but there was no difference seen in the heart rate (Figure 3.2B; 565 
±21 vs 555 ±30 bpm, KO vs WT, n=8).   
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Figure 3.1. Typical blood pressure and heart rate traces in 
anaesthetised Gnasxl knockout mice and wildtype siblings.  
Blood pressure was recorded in urethane-chloralose anaesthetised Gnasxl 
knockout mice (B; right) and wildtype siblings (A; left).  
(i) Typical blood pressure trace recorded at high resolution. Signal was AC 
coupled and amplified 10-100 times, depending on signal strength. Heart 
beats were annotated using Wabp from the Physionet suite of programs; 
beat annotations are shown as red bars.  
(ii) Typical raw unamplified blood pressure trace recorded by DC coupling.  
(iii) Heart beat intervals associated with the shown blood pressure trace. 
(iv) Instantaneous heart rate as calculated from the interval series shown. 
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Figure 3.2. Basal cardiovascular parameters in anaesthetised Gnasxl 
knockout mice and wildtype siblings.  
Blood pressure and heart rate were recorded in urethane-chloralose 
anaesthetised Gnasxl knockout mice and dose-matched wildtype siblings.  
(A) Mean basal blood pressure was significantly elevated in Gnasxl knockout 
mice (*p≤0.05 by paired t-test, n=8).  
(B) There was no significant difference in mean basal heart rate between 
wildtypes and knockouts.  
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3.3.1.2 Blood pressure responses to reserpine in anaesthetised Gnasxl 
knockouts 
In order to determine whether the elevated blood pressure seen in the 
knockouts was due to increased SNS stimulation of the cardiovascular 
system, the mice were injected with the sympatholytic reserpine at 2 mg/kg 
ip. Both wildtypes and knockouts had a similar response to vehicle (Figure 
3.3A), but knockouts had a more pronounced response to reserpine than 
wildtypes (Figure 3.3B).  
This is more objectively visible when the blood pressure is averaged before 
injection, after vehicle injection, and after reserpine injection (Figure 3.3C). It 
is clear from this that the blood pressure drops to a similar extent in wildtypes 
and knockouts after vehicle injection, but the knockouts have a greater 
response to reserpine.  
To take into account this gradual decrease in BP over time, the response to 
reserpine was calculated as blood pressure response to reserpine relative to 
the blood pressure response to vehicle; this was calculated individually for 
each mouse, so each mouse was its own internal control. In this way, 
knockouts were found to have a significantly greater response to reserpine 
compared to dose-matched sibling wildtypes (Figure 3.3D; -7.0 ±1.3 vs -0.5 
±1.9 mmHg, KO vs WT; p≤0.05 by paired t-test, n=5).  
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Figure 3.3. Cardiovascular response to reserpine in anaesthetised 
Gnasxl knockout mice and wildtype siblings.  
Blood pressure was recorded in urethane-chloralose anaesthetised Gnasxl 
knockout mice and dose-matched wildtype siblings.  
(A) Blood pressure responses to vehicle over time.  
(B) Blood pressure responses over time to reserpine 2 mg/kg ip.  
(C) Due to the highly variable and declining blood pressure, responses were 
calculated as blood pressure change after reserpine relative to the change 
after vehicle (ie. blood pressure decrease after reserpine minus decrease 
after vehicle, individually for each mouse). In this way, knockouts had a 
significantly greater relative blood pressure response to reserpine compared 
to wildtypes (*p≤0.05 by paired t-test; responses were paired between dose-
matched siblings). 
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3.3.2 ECG telemetry in conscious mice 
Radiotelemetry was used to record ECG from conscious freely-moving 
animals (Figure 3.4 for representative data); this avoided the potentially 
significant effects to the cardiovascular system of the anaesthesia used in 
the earlier experiments.  
3.3.2.1 Heart rate in conscious Gnasxl knockout mice 
Circadian changes in heart rate and locomotor activity were investigated in 
adult knockouts (3.5A/C). Knockouts had significantly elevated heart rate at 
night (Figure 3.5B; 630 ±14 vs 590 ±10 bpm KO vs WT, p≤0.05 by t-test, 
n=12), but there were no significant differences in daytime heart rate (Figure 
3.5B) or in locomotor activity at any time (Figure 3.5D). Autonomic control of 
the cardiovascular system was investigated by injection of reserpine and 
atropine as sympathetic and parasympathetic antagonists, respectively.  
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Figure 3.4. Typical ECG and heart rate traces in conscious Gnasxl 
knockout mice and wildtype siblings.  
ECG was recorded at high resolution from conscious freely moving adult 
Gnasxl knockout mice (B; right) and wildtype siblings (A; left) using 
radiotelemeters.  
(i) Typical raw ECG trace from the active night period.  
(ii) Zoomed in region of the same ECG trace showing beat architecture. 
Heart beats were annotated using a custom program (red bars).  
(iii) Typical heart beat interval series. 
(iv) Instantaneous heart rate as calculated from the beat interval series 
shown.  
(v) Zoomed in region of the same instantaneous heart rate trace showing 
substantial heart rate variability over time.  
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Figure 3.5. Circadian heart rate and activity in conscious Gnasxl 
knockouts.  
Heart rate and activity were measured continuously by telemetry from 
conscious freely moving adult Gnasxl knockouts and wildtype siblings.  
(A) Circadian variation in heart rate, averaged into 1-hour bins over 24 hours.  
(B) Knockouts showed significantly elevated heart rate at night (*p≤0.05 by t-
test, n=12).  
(C) Circadian variation in locomotor activity, averaged into 1-hour bins over 
24 hours.  
(D) No significant changes were seen in average activity measures between 
wildtypes and knockouts. 
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3.3.2.2 Sympathetic control of heart rate in conscious Gnasxl knockout 
mice 
The origin of the elevated heart rate in knockouts was investigated by 
injecting reserpine ip at 1 mg/kg. Heart rate response to reserpine over time 
for wildtypes and knockouts is shown in Figure 3.6A. On average, reserpine 
caused a significant decrease in heart rate in knockouts (Figure 3.6B; 531 
±23 to 455 ±12 bpm, p≤0.05 by paired t-test, n=8), but not in wildtypes 
(Figure 3.6B; 516 ±21 to 471 ±41 bpm, n=8). There was no significant 
difference in average heart rate response to reserpine between the two 
genotypes (Figure 3.6C; -73 ±30 vs -42 ±46 bpm, KO vs WT, n=8). 
3.3.2.3 Parasympathetic control of heart rate in conscious Gnasxl 
knockout mice 
Parasympathetic control of the cardiovascular system in Gnasxl knockouts 
was investigated by injection of atropine 2 mg/kg ip. Heart rate response to 
atropine over time for wildtypes and knockouts is shown in Figure 3.7A. On 
average, atropine significantly increased heart rate in knockouts (Figure 
3.7B; 551 ±16 to 591 ±19 bpm, p≤0.05 by paired t-test, n=6), but not in 
wildtypes (Figure 3.7B; 533 ±28 to 552 ±17 bpm, n=6). There was no 
significant difference in average heart rate response to atropine between the 
two genotypes (Figure 3.7C; 40 ±11 vs 19 ±21 bpm, KO vs WT, n=6). 
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Figure 3.6. Heart rate responses to reserpine in conscious Gnasxl 
knockout mice.  
Heart rate was recorded using ECG telemetry from conscious Gnasxl  
knockout mice and wildtype siblings. The sympatholytic reserpine was 
injected at 1 mg/kg ip. 
(A) Heart rate response to reserpine over time.  
(B) Knockouts had a significant decrease in heart rate in response to 
reserpine (*p≤0.05 by paired t-test, n=8), which was not seen in wildtypes.  
(C) Heart rate responses to reserpine compared to vehicle responses in 
wildtype and knockouts. 
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Figure 3.7. Heart rate responses to atropine in conscious Gnasxl 
knockout mice.  
Heart rate was recorded using ECG telemetry from conscious Gnasxl  
knockout mice and wildtype siblings. The parasympatholytic atropine was 
injected at 2 mg/kg ip.  
(A) Heart rate response to atropine over time.  
(B) Knockouts had a significant increase in heart rate in response to atropine 
(*p≤0.05 by paired t-test, n=6).  
(C) Heart rate responses of atropine compared to saline in wildtypes and 
knockouts. 
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3.3.3 Thermogenesis control in Gnasxl knockout mice 
Gnasxl knockout mice have previously been shown to have elevated brown 
adipose tissue (BAT) expression of uncoupling protein 1 (UCP1), the BAT-
specific uncoupling protein (Xie et al., 2006). BAT expression levels of UCP1 
increase in response to SNS stimulation of BAT (Cannon & Nedergaard, 
2004), so this suggests first that Gnasxl knockouts have elevated SNS 
stimulation of the BAT, suggesting in turn that they have elevated 
thermogenesis, and therefore elevated core body temperature.  
BAT signalling changes in Gnasxl knockouts were explored by Western blot 
to investigate phosphorylation changes to hormone sensitive lipase (HSL), 
which is known to control rates of lipolysis in response to SNS stimulation of 
BAT (Cannon & Nedergaard, 2004). Western blot for P-HSL compared to 
HSL is shown in Figure 3.8Ai. No significant changes were seen when the 
bands were quantified using pixel densitometry (Figure 3.8Aii; 1.2 ±0.7 vs 0.9 
±0.2 ratio P-HSL/HSL, WT vs KO n=2).  
The physiological effects of the Gnasxl knockout on body temperature were 
also investigated. Body temperature was recorded following loss of 
consciousness precisely 3 minutes after injection of urethane-chloralose 
anaesthesia. Knockouts were found to have significantly elevated body 
temperature compared to dose-matched sibling wildtypes (Figure 3.8B; 38.1 
±0.3 vs 36.9 ±0.4 °C, KO vs WT, p≤0.05 by paired t-test, n=7).  
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Figure 3.8. Physiological control of thermogenesis in Gnasxl knockout 
mice.  
(A) Hormone-sensitive lipase phosphorylation levels in brown adipose tissue 
of Gnasxl knockouts and wildtype siblings were investigated by western blot 
(i). Phosphorylation levels, quantified using ImageJ (ii), were unchanged in 
Gnasxl knockouts compared to wildtype siblings (n=2).  
(B) Body temperature was significantly elevated in urethane-chloralose 
anaesthetised Gnasxl knockouts compared to dose-matched wildtype 
siblings (*p≤0.05 by paired t-test, n=7). 
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3.4 Discussion 
Xie et al. showed that mice lacking XLαs have a hypermetabolic phenotype 
caused by elevated SNS stimulation of the brown and white adipose tissues 
(Xie et al., 2006). They postulated that the elevated SNS activity might be a 
global effect (Xie et al., 2006), which would affect other tissues such as the 
cardiovascular system. This hypothesis is supported by the restricted 
expression pattern of XLαs in the brain, which includes a number of regions 
crucial for control of the SNS (Krechowec et al., 2012). The aim of this 
chapter was to investigate this hypothesis in detail, focussing on autonomic 
control of the cardiovascular system in adult Gnasxl knockout mice. 
Firstly blood pressure was recorded in adult Gnasxl knockout mice to provide 
an indication of overall cardiovascular stimulation. Non-invasive tail 
plethysmography system was first trialled in conscious mice, and while 
wildtype mice gave clear readings, Gnasxl knockouts did not (data not 
shown). There are a number of potential causes for this: perhaps the 
knockouts had poor blood circulation to the tail, or maybe they didn’t respond 
in the same way as the wildtype mice to being housed at 30 °C for taking 
measurements, or maybe they responded differently to the stressful 
environment of being restrained.  
As with the Schlager mice (Davern et al., 2010), it is likely that the Gnasxl  
knockout mice might have an elevated stress response. Due to these 
problems with measuring cardiovascular parameters in conscious mice by 
non-invasive plethysmography, cannulation was used in anaesthetised mice.  
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Arterial cannulation was used to record arterial pressure in real time, 
providing basal blood pressure and heart rate data, as well as blood 
pressure responses to reserpine. Following a pilot cannulation experiment, it 
was found that the anaesthetic was having a substantial effect on the 
cardiovascular system (data not shown). Therefore, the anaesthetic was 
modified to include α-chloralose so as to reduce the concentration of 
urethane required for full anaesthesia (Dalkara et al., 1995; Kass et al., 
1998). Additionally the mice were strictly dose-matched by anaesthetic 
between sibling groups, to balance any potential detrimental effects to the 
cardiovascular system.  
Under these conditions, knockouts were found to have elevated blood 
pressure (Figure 3.2A), as well as a greater response to the sympatholytic 
reserpine (Figure 3.3D). No difference was seen in basal heart rate (Figure 
3.2B) or in the heart rate response to reserpine (data not shown).  
The increased basal blood pressure in Gnasxl knockouts suggests the mice 
have elevated cardiovascular stimulation, and the inhibition of peripheral 
sympathetic nerve activity by reserpine indicates this is caused by elevated 
SNS stimulation of the heart and vasculature . The principle behind this 
experiment is similar to that used by Davern et al. to investigate SNS control 
of the cardiovascular system in Schlager hypertensive mice, where the 
ganglionic blocker pentolinium was used to inhibit SNS activity (Davern et al., 
2009).  
However, rather than pentolinium which blocks both SNS and PNS ganglia, 
reserpine was used because it inhibits specifically outflow from sympathetic 
Chapter 3: Cardiovascular control in Gnasxl knockouts 
85 
 
nerves. Davern et al. found that the elevated blood pressure in Schlager 
hypertensive mice was abolished after ganglionic blockade, after which the 
hypertensive mice had comparable blood pressure to wildtypes. A similar 
result was seen here, where the elevated blood pressure in the Gnasxl  
knockouts was counteracted by reserpine, quantified as a significantly 
greater blood pressure response. However, the Schlager study was 
performed on conscious mice, avoiding the potentially detrimental effects of 
anaesthesia on cardiovascular parameters.  
Using ECG telemetry in conscious freely moving mice, adult male Gnasxl  
knockout mice were found to have elevated resting heart rate at night (Figure 
3.5B). It is interesting to note that at certain time points during the day 
Gnasxl knockouts appear to have elevated blood pressure, but it is 
consistently higher at night, suggesting this is the time that the biggest 
phenotypic effects occur. This might be expected in a model of elevated SNS 
activity, as the sympathetic activity increases at night. 
Reserpine and atropine were used to investigate the relative contributions of 
the opposing branches of the autonomic nervous system to the elevated 
heart rate. As with the anaesthetised mice, conscious mice were found to 
have a greater response to reserpine, which caused a significant decrease in 
heart rate in knockouts but not in wildtypes (Figure 3.6B).  
Interestingly, the knockouts were also found to have a greater response to 
atropine, which caused a significant increase in heart rate in knockouts but 
not in wildtypes (Figure 3.7B). This suggests that the knockout mice 
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paradoxically have elevated tonic stimulation of the cardiovascular system by 
both the SNS and PNS.  
However, these results do not necessarily mean that the mice have elevated 
sympathetic and parasympathetic nerve activity, as the effects might have a 
peripheral cause, for example varying levels of peripheral receptor 
expression (Young & Davisson, 2011). Therefore, this will be investigated 
further in the next chapter by analysis of heart rate variability in Gnasxl  
knockouts, as an indirect marker of sympathetic and parasympathetic 
nervous system stimulation of the cardiovascular system.  
Although it has been mentioned that XLαs likely affects central SNS control 
by its expression in such regions as the PVN and DMH, it is also possible 
that XLαs has a direct effect on the PNS, as it is also expressed in brain 
regions crucial for PNS control, including the NTS and the nucleus ambiguus 
(Krechowec et al., 2012). 
Gnasxl knockout mice have previously been shown to exhibit markers of 
elevated metabolism, in particular elevated BAT lipolysis (Xie et al., 2006), 
but the physiological effects have never been documented. Loss of XLαs had 
no significant effects on hormone-sensitive lipase (HSL) phosphorylation in 
BAT (Figure 3.8A), which is a marker of the degree of SNS-mediated 
lipolysis (Egan et al., 1992; Cannon & Nedergaard, 2004).  
However, Gnasxl knockouts were found to have elevated core body 
temperature (Figure 3.8B). The elevated body temperature fits with the 
concept of Gnasxl knockouts having elevated SNS stimulation of the BAT 
causing increased thermogenesis, resulting in the lean phenotype. It is 
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possible that the very low levels of HSL phosphorylation resulted in 
inaccurate quantification; very high levels of protein had to be loaded onto 
the gel in order to have a signal produced (ie. 100 µg of protein, compared to 
the usual 20-40 µg).  
In summary, the phenotype of Gnasxl knockout mice is shown here to 
include elevated blood pressure, heart rate and body temperature, which 
would suggest a systemic change to cause such consistent effects. 
Furthermore, the changes to the cardiovascular system appear likely to be 
caused by elevated SNS stimulation, although possible changes to the PNS 
remain less clear.  
The data support the hypothesis first described by Xie et al. (Xie et al., 2006) 
that Gnasxl knockout mice have a systemic increase in SNS activity that is 
responsible for the metabolic phenotype previously described, as well as the 
cardiovascular phenotype described here. This implies that XLαs functions in 
the CNS to inhibit SNS outflow, resulting in elevated SNS activity when XLαs 
is knocked out. In the next chapter, autonomic control of the cardiovascular 
system in Gnasxl knockouts will be investigated in more detail by HRV 
analysis in conscious mice. 
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4 Autonomic control of heart rate 
variability in mice lacking XLαs 
4.1 Introduction 
In the previous chapter it was shown that mice lacking the signalling protein 
XLαs have elevated blood pressure and heart rate, with the likely explanation 
that this is caused by increased sympathetic nervous system (SNS) 
stimulation of the cardiovascular system. The aim of this chapter is to 
investigate this further using heart rate variability (HRV) analysis, as an 
indirect measure of the degree of autonomic stimulation of the cardiovascular 
system by the SNS and parasympathetic nervous system (PNS). 
4.1.1 CNS control of the cardiovascular system 
Heart rate and blood pressure are tightly controlled by the CNS, as well as 
other hormonal and peripheral factors (Figure 4.1) (Malliani et al., 1991; 
Parati et al., 1995; Parati et al., 2006). Of particular importance is the 
balance between the sympathetic and parasympathetic branches of the 
autonomic nervous system.  
Factors controlling the cardiovascular system cause variations in blood 
pressure and heart rate, which are known to occur at characteristic 
frequencies (Akselrod et al., 1981). For example, it is known that 
cardiovascular control by the PNS occurs at high frequencies, and the SNS 
dominates lower frequency oscillations. However, the exact origin of the 
Chapter 4: Heart rate variability control in Gnasxl knockouts 
89 
 
slower oscillations remain unclear. Firstly is the central oscillator theory, 
which postulates that the sympathetic rhythms are generated by brain stem 
circuits. Secondly is the baroreflex theory, which suggests that the delay in 
feedback of the baroreflex loop results in oscillations to sympathetic and 
parasympathetic control of the cardiovascular system (Papaioannou, 2007).  
In humans, HRV has been extensively analysed, and the methods for 
evaluating HRV have been standardised (Camm et al., 1996). In fact, HRV is 
used as a diagnostic tool in investigations into cardiovascular disease, for 
example for diagnosing autonomic neuropathy (Ewing et al., 1985), or for 
detecting changes to HRV which occur before a cardiac event, for example 
predicting ventricular tachycardia in patients with coronary heart disease 
(Huikuri et al., 1993). 
4.1.2 HRV analysis 
Investigations into autonomic control in mice using HRV analysis are 
common due to the widespread use of transgenic and genetically modified 
mice (Uechi et al., 1998; Ecker et al., 2006; Senador et al., 2009; Griffioen et 
al., 2011). However, in mice, and other laboratory animals, HRV parameters 
have not been thoroughly standardised, although some efforts have been 
made in that direction (Gehrmann et al., 2000; Thireau et al., 2008).  
The use of HRV analysis to quantify autonomic activity is a controversial 
topic (Goldstein et al., 2011), but a number of reports show that HRV can 
give an accurate indication of autonomic activity (Farah et al., 2006; Baudrie 
et al., 2007; Laude et al., 2008). The main benefit of HRV analysis is that it is 
non-invasive, and therefore can be used in conscious freely moving animals, 
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and it doesn’t require culling of the animal, and therefore can be used to give 
responses to drugs or other interventions (Young & Davisson, 2011).  
4.1.3 Aims 
A number of different HRV analyses will be explored in this study, including 
standard time-domain analyses and power spectral analysis using fast 
Fourier transforms (FFTs). However, due to the inconsistencies in the HRV 
analyses reported in the literature, these methods will first be empirically 
verified using reserpine and atropine to inhibit cardiovascular regulation by 
the SNS and PNS, respectively. Once validated, HRV will be used to 
investigate in detail the control of autonomic stimulation of the cardiovascular 
system in Gnasxl knockout mice, with a high degree of confidence.  
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Figure 4.1. The complexities of cardiovascular control by the CNS.  
Blood pressure control is mediated by a number of systems, including the 
heart, kidneys and vasculature. CNS control is exerted by the autonomic 
nervous system, including the sympathetic (light grey) and parasympathetic 
(dark grey dashed) nervous systems, as well as hormonal control, for 
example vasoactive substances released from the pituitary. The CNS is 
controlled by a number of inputs, including the baroreflex. Taken from 
(Young & Davisson, 2011).  
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4.2 Methods 
Adult male Gnasxl knockout mice and wildtype siblings were implanted with 
electrocardiogram (ECG) telemeters. ECG was recorded at high frequency 
(5 kHz) and heart beats were annotated to within 0.2 ms accuracy. HRV 
analysis was performed using Kubios HRV program (Niskanen et al., 2004), 
except for Lomb spectra, which were produced using the Lomb application 
from the Physionet suite of HRV programs (Goldberger et al., 2000). For 
further details see chapter 2.  
4.3 Results 
4.3.1 Validating methods of HRV analysis 
A number of methods for analysing HRV were tested by injection of 
reserpine and atropine, to investigate control by the sympathetic and 
parasympathetic nervous systems, respectively. 
4.3.1.1 Time domain HRV analyses 
The most straightforward methods for analysing HRV are so-called time 
domain measures, including the standard deviation of normal RR intervals 
(SDNN) and the root mean square of successive differences (RMSSD) 
(Camm et al., 1996). SDNN is simply the overall standard deviation of heart 
beat intervals over a time period, and gives a crude estimate of long-term 
changes to the heart rate, ie. giving information about SNS control. RMSSD 
quantifies the degree of beat-to-beat variation in a heart rate series, 
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providing information of short-term changes to the heart rate, ie. about the 
PNS.  
A typical resting RR interval series is shown in Figure 4.2Ai, with the 
associated SDNN and RMSSD values. Following reserpine injection and loss 
of SNS input to the cardiovascular system (Figure 4.2Aii), SDNN drops but 
the RMSSD remains high. On the other hand, following atropine injection and 
loss of PNS input (Figure 4.2Aiii), SDNN remains high and RMSSD drops.  
These responses were quantified for a sample of wildtype mice, showing a 
significant decrease in SDNN (Figure 4.2B; 5.8 ±0.1 to 4.0 ±0.7 ms; p≤0.05 
by paired t-test, n=8), but not RMSSD (Figure 4.2B; 3.5 ±0.4 to 3.0 ±0.4 ms; 
n=8) after reserpine injection. After atropine injection, there was a significant 
decrease in RMSSD (Figure 4.2C; 2.8 ±0.3 to 1.6 ±0.4 ms; p≤0.05 by paired 
t-test, n=6), with no significant change to SDNN (Figure 4.2C; 4.9 ±0.5 to 3.6 
±0.2 ms; n=6). 
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Figure 4.2. Time domain HRV analysis.  
Heart rate was recorded from conscious CD1 wildtype mice at high 
resolution (within 0.2 ms). HRV analysis using the time domain measures 
standard deviation of normal RR intervals (SDNN) and root mean square of 
successive differences (RMSSD) were validated by injection of reserpine ip 
at 1 mg/kg to inhibit SNS activity and injection of atropine ip at 2 mg/kg to 
inhibit PNS activity. SDNN and RMSSD were calculated from 3-minute 
sections of clean and stable heart rate; the units of both are in ms. 
(A) Typical RR interval series over 60s in control conditions (i), after 
reserpine injection (ii) and after atropine injection (iii). SDNN and RMSSD 
values for those time series are shown; note the reduction in SDNN after 
reserpine and the reduction in RMSSD after atropine.  
(B) SDNN was significantly reduced after reserpine injection (*p≤0.05 by 
paired t-test, n=8).  
(C) RMSSD was significantly reduced after atropine injection (*p≤0.05 by 
paired t-test, n=6). 
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4.3.1.2 Nonlinear HRV analysis 
Nonlinear HRV parameters can provide more in depth detail into heart rate 
control. In this study, the nonlinear HRV parameter investigated was  
Poincaré analysis, in which an RR interval series is plotted on a scatter plot, 
with each interval plotted on the x-axis against the following interval on the y-
axis (Figure 4.3Ai for a typical example in a wildtype mouse). This plot shows 
a distribution of the beat-to-beat variation in heart rate, and can provide 
information about long- and short-term HRV effects depending upon the 
distribution of the data. This is quantified by calculation of the standard 
deviation at 45° angles of the axes (see Figure 4.3Ai).  
SD1 quantifies beat-to-beat variation, and is therefore a marker of short-term 
PNS activity. SD2 quantifies overall variation throughout the RR series, and 
is therefore indicative of long-term SNS activity. Accordingly, reserpine 
injection causes a reduction in SD2 (Figure 4.3Aii for typical example), 
whereas atropine injection causes a reduction in SD1 (Figure 4.3Aiii for 
typical example).  
These responses were quantified for a sample of wildtype mice, showing a 
significant decrease in SD2 (Figure 4.3B; 7.7 ±0.2 to 5.2 ±1.0 ms; p≤0.05 by 
paired t-test, n=8), but not SD1 (Figure 4.3B; 2.5 ±0.3 to 2.1 ±0.4 ms; n=8) 
after reserpine injection. After atropine injection, there was a significant 
decrease in SD1 (Figure 4.3C; 2.0 ±0.2 to 1.1 ±0.3 ms; p≤0.05 by paired t-
test, n=6), with no significant change to SD2 (Figure 4.3C; 6.5 ±0.8 to 4.9 
±0.3 ms; n=6). 
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Figure 4.3. Nonlinear HRV analysis using Poincaré plots.  
Heart rate was recorded from conscious CD1 wildtype mice at high 
resolution (within 0.2 ms). HRV analysis using nonlinear Poincaré analysis 
was validated by injection of reserpine ip at 1 mg/kg to inhibit SNS activity 
and injection of atropine ip at 2 mg/kg to inhibit PNS activity. Poincaré plots 
were produced by plotting each RR interval on the x-axis against the 
successive RR interval on the y-axis. The standard deviation was calculated 
at 45° angles of the axes to give the values SD1 and SD2, from 3-minute 
sections of clean and stable heart rate. 
(A) Typical Poincaré plots in adult CD1 mice under control conditions (i), 
after reserpine injection (ii) and after atropine injection (iii). Note the 
reduction of SD2 after reserpine and the reduction in SD1 after atropine.  
(B) SD2 was significantly reduced after reserpine injection (*p≤0.05 by paired 
t-test, n=8).  
(C) SD1 was significantly reduced after atropine injection (*p≤0.05 by paired 
t-test, n=6). 
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4.3.1.3 Frequency domain HRV analyses 
There is arguably far more information to be gained about heart rate control 
by HRV analysis in the frequency domain. This involves producing power 
spectra, which graphically represent the degree of variability across a range 
of frequencies. A number of methods can be used, including fast Fourier 
transforms (FFTs), autoregressive spectra and Lomb transforms.  
Pilot investigations showed Kubios HRV program to be the most intuitive and 
user friendly method, as well as providing a visual interface that facilitated 
analysis (Niskanen et al., 2004), and was therefore used for HRV analysis by 
FFT and autoregressive spectra. In each case the heart rate trace was 
visually inspected for 3-minute sections of clean and stable heart rate.  
Heart rate was resampled at 20Hz; FFTs were performed using Welch’s 
periodogram with 32-second windows with 50 % overlap, and autoregressive 
spectra were produced using a 32-order model. Lomb power spectra were 
produced from raw non-resampled heart rate data using Physionet 
(Goldberger et al., 2000). 
Power spectral analysis has the added complication that the frequencies of 
heart rate variability that correspond to sympathetic and parasympathetic 
activity in the mouse are inconsistent in the literature. Therefore, as part of 
this investigation, the frequencies associated with the SNS and PNS were 
empirically determined by injection of reserpine and atropine , respectively.  
The high frequency (HF) domain is reported to reflect only PNS stimulation; 
this region is commonly reported to extend from around 1.5 Hz up to 5.0 Hz 
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(Thireau et al., 2008), with the condition that the breathing peak be included. 
In this study, the breathing peak was occasionally found to lie as low as 1.2 
Hz, so the lower boundary for the HF band was set to 1.0 Hz in order to 
guarantee inclusion of the breathing peak.  
The low frequency (LF) domain is reported to reflect both SNS and PNS 
stimulation; the lower boundary can be between 0.15 and 0.4 Hz, and the 
upper boundary will generally correspond to the lower boundary of the HF 
region (Thireau et al., 2008). Recently, a thorough investigation by Baudrie et 
al. into the optimal LF frequency bandings in mice gave a range of 0.15 – 
0.60 Hz (Baudrie et al., 2007).  
In agreement with this LF range, it was found in this study that virtually all 
power spectral density was lost in the LF region down to 0.15 Hz following 
reserpine injection (see for example Figure 4.4Aii); therefore this was chosen 
as the lower cut-off. The chosen bandings were therefore: LF 0.15 – 1.0 Hz, 
HF 1.0 – 5.0 Hz, and these were used for validating HRV analysis by FFT, 
autoregressive and Lomb power spectra. Similar results were found for each 
of these methods, as detailed below. 
Typical FFT power spectra are shown under resting conditions (Figure 
4.4Ai), after reserpine injection showing loss of LF power (Figure 4.4Aii), and 
after atropine injection showing loss of both LF and HF power (Figure 
4.4Aiii).  
These responses were quantified for a sample of wildtype mice, showing that 
after reserpine injection both LF power (Figure 4.4B; 4.3 ±0.9 to 1.2 ±0.4 
ms2/Hz; p≤0.05 by paired t-test, n=8) and LF/HF ratio (Figure 4.4B; 1.2 ±0.3 
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to 0.5 ±0.1; p≤0.05 by paired t-test, n=8) were significantly reduced with no 
change to HF power (Figure 4.4B; 4.5 ±0.9 to 3.5 ±0.9 ms2/Hz; n=8). 
Following atropine injection, both LF power (Figure 4.4C; 2.8 ±0.5 to 0.7 ±0.3 
ms2/Hz; p≤0.05 by paired t-test, n=6) and HF power (Figure 4.4C; 3.0 ±0.6 to 
1.2 ±0.5 ms2/Hz; p≤0.05 by paired t-test, n=6) were significantly reduced, 
with no change to LF/HF ratio (Figure 4.4C; 1.5 ±0.2 to 1.1 ±0.3; n=6).  
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Figure 4.4. Frequency domain HRV analysis by fast Fourier transform.  
Heart rate was recorded from conscious CD1 wildtype. Frequency domain 
HRV analysis using fast Fourier transform (FFT) was validated by injection of 
reserpine ip at 1 mg/kg to inhibit SNS activity and injection of atropine ip at 2 
mg/kg to inhibit PNS activity. FFT spectra were produced from 3-minute 
sections of clean and stable heart rate resampled at 20 Hz using Welch’s 
algorithm with 32-second windows with 50 % overlap.  
(A) Typical FFT spectra under control conditions (i), after reserpine injection 
(ii) and after atropine injection (iii). Note the breathing peak at ~2.2 Hz in the 
high frequency (HF) region and the total loss of power spectral density in the 
low frequency (LF) region down to 0.15 Hz. 
(B) LF power and LF/HF ratio were significantly reduced after reserpine 
injection (*p≤0.05 by paired t-test).  
(C) LF and HF power were significantly reduced after atropine injection 
(*p≤0.05 by paired t-test).  
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Typical autoregressive spectra are shown under resting conditions (Figure 
4.5Ai), after reserpine injection showing loss of LF power (Figure 4.5Aii), and 
after atropine injection showing loss of LF and HF power (Figure 4.5Aiii).  
These responses were quantified for a sample of wildtype mice, showing that 
after reserpine injection both LF power (Figure 4.5B; 4.1 ±0.8 to 1.1 ±0.3 
ms2/Hz; p≤0.05 by paired t-test, n=8) and LF/HF ratio (Figure 4.5B; 1.3 ±0.3 
to 0.5 ±0.1; p≤0.05 by paired t-test, n=8) were significantly reduced with no 
change to HF power (Figure 4.5B; 4.5 ±0.9 to 3.5 ±0.9 ms2/Hz; n=8). 
Following atropine injection, both LF power (Figure 4.5C; 2.7 ±0.5 to 0.6 ±0.3 
ms2/Hz; p≤0.05 by paired t-test, n=6) and HF power (Figure 4.5C; 3.0 ±0.6 to 
1.2 ±0.5 ms2/Hz; p≤0.05 by paired t-test, n=6) were significantly reduced, 
with no change to LF/HF ratio (Figure 4.5C; 1.4 ±0.2 to 0.9 ±0.2; n=6).  
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Figure 4.5. Frequency domain HRV analysis using autoregressive 
power spectra.  
Heart rate was recorded from conscious CD1 wildtype mice at high 
resolution (within 0.2 ms). Frequency domain HRV analysis using 
autoregressive spectra was validated by injection of reserpine ip at 1 mg/kg 
to inhibit SNS activity and injection of atropine ip at 2 mg/kg to inhibit PNS 
activity. Autoregressive spectra were produced from 3-minute sections of 
clean and stable heart rate resampled at 20 Hz using a 32-order model.  
(A) Typical autoregressive spectra under control conditions (i), after 
reserpine injection (ii) and after atropine injection (iii). Note the breathing 
peak at ~2.2 Hz in the high frequency (HF) region and the almost complete 
loss of power spectral density in the low frequency (LF) region down to 0.15 
Hz. 
(B) LF power and LF/HF ratio were significantly reduced after reserpine 
injection (*p≤0.05 by paired t-test).  
(C) LF and HF power were significantly reduced after atropine injection 
(*p≤0.05 by paired t-test). 
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Typical Lomb power spectra are shown under resting conditions (Figure 
4.6Ai), after reserpine injection showing loss of LF power (Figure 4.6Aii), and 
after atropine injection showing loss of LF and HF power (Figure 4.6Aiii).  
These responses were quantified for a sample of wildtype mice, showing that 
after reserpine injection both LF power (Figure 4.6B; 4.5 ±0.9 to 1.2 ±0.4 
ms2/Hz *10^6; p≤0.05 by paired t-test, n=8) and LF/HF ratio (Figure 4.6B; 1.2 
±0.3 to 0.4 ±0.1; p≤0.05 by paired t-test, n=8) were significantly reduced with 
no change to HF power (Figure 4.6B; 5.3 ±1.0 to 4.3 ±1.1 ms2/Hz *10^6; 
n=8). Following atropine injection, both LF power (Figure 4.6C; 2.5 ±0.7 to 
0.6 ±0.3 ms2/Hz *10^6; p≤0.05 by paired t-test, n=6) and HF power (Figure 
4.6C; 3.0 ±0.8 to 1.3 ±0.6 ms2/Hz *10^6; n=6) were significantly reduced, 
with no change to LF/HF ratio (Figure 4.6C; 1.0 ±0.2 to 0.7 ±0.2; n=6).  
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Figure 4.6. Frequency domain HRV analysis using Lomb power spectra.  
Heart rate was recorded from conscious CD1 wildtype mice at high 
resolution (within 0.2 ms). Frequency domain HRV analysis using Lomb 
power spectra was validated by injection of reserpine ip at 1 mg/kg to inhibit 
SNS activity and injection of atropine ip at 2 mg/kg to inhibit PNS activity. 
Lomb spectra were produced from 3-minute sections of clean and stable 
heart rate using the Lomb periodogram, using native (ie. non-resampled) 
heart rate.  
(A) Typical Lomb spectra under control conditions (i), after reserpine 
injection (ii) and after atropine injection (iii). Note the breathing peak at ~2.2 
Hz in the high frequency (HF) region and the almost complete loss of power 
spectral density in the low frequency (LF) region down to 0.15 Hz. 
(B) LF power and LF/HF ratio were significantly reduced after reserpine 
injection (*p≤0.05 by paired t-test).  
(C) LF and HF power were significantly reduced after atropine injection 
(*p≤0.05 by paired t-test). 
LF and HF powers in (B) and (C) are shown as ms2/Hz *10^6. 
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The HRV changes calculated here by power spectral analysis fit previously 
reported HRV analyses in mice, where HF power is indicative of 
parasympathetic stimulation of the cardiovascular system, and LF/HF ratio is 
indicative of sympathovagal balance (Young & Davisson, 2011). These 
parameters were therefore considered valid for use in HRV analysis in 
Gnasxl knockout mice.  
However, the remainder of this chapter uses FFT’s to further analyse HRV 
control in Gnasxl knockout mice, because these are most commonly used in 
the literature, they are much easier to produce than Lombs, and they were 
more reliable than autoregressive spectra (LF/HF decreased a lot after 
atropine using autoregressive spectra, p=0.085). 
4.3.2 HRV control in conscious Gnasxl knockout mice 
Heart rate variability (HRV) was investigated in conscious Gnasxl knockout 
mice using fast Fourier transforms (FFTs), which were fully validated for 
analysis of parasympathetic activity and sympathovagal balance. HF power 
was used as an indicator of PNS activity, and LF/HF ratio was used as an 
indicator of SNS activity, specifically as a marker of sympathovagal balance.  
4.3.2.1 HRV responses to reserpine in conscious Gnasxl knockouts 
Reserpine caused a decrease in LF/HF ratio over time in both wildtypes and 
knockouts (Figure 4.7A). This was a significant decrease in both wildtypes 
(Figure 4.7B; 1.38 ±0.31 to 0.47 ±0.09, p≤0.05 by paired t-test, n=8) and 
knockouts (Figure 4.7B; 1.39 ±0.22 to 0.26 ±0.06, p≤0.05 by paired t-test, 
n=8). However, the percentage decrease in LF/HF ratio was significa ntly 
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greater in knockouts compared to wildtypes (Figure 4.7C; -80 ±5 vs -48 ±13 
% KO vs WT, p≤0.05 by t-test, n=8). 
4.3.2.2 HRV responses to atropine in conscious Gnasxl knockouts  
Atropine caused a decrease in HF power over time in both wildtypes and 
knockouts (Figure 4.8A). This was a significant decrease in both wildtypes 
(Figure 4.8B; 3.0 ±0.6 to 1.2 ±0.5 ms2/Hz, p≤0.05 by paired t-test, n=6) and 
knockouts (Figure 4.8B; 2.7 ±0.7 to 0.6 ±0.2 ms2/Hz, p≤0.05 by paired t-test, 
n=6). However, there was no significant difference in % decrease between 
wildtypes and knockouts (Figure 4.8C; -61 ±16 vs -77 ±6 % in WT vs KO, 
n=6).  
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Figure 4.7. HRV responses to reserpine in conscious Gnasxl knockout 
mice.  
Heart rate was recorded from conscious Gnasxl knockout mice and wildtype 
siblings at high resolution (within 0.2 ms). FFT spectra were produced from 
3-minute sections of clean and stable heart rate resampled at 20 Hz using 
Welch’s algorithm with 32-second windows with 50 % overlap. The LF/HF 
ratio was used as an indicator of sympathetic stimulation of the 
cardiovascular system, and was calculated using the bandings LF 0.15 -1.0 
Hz, HF 1.0-5.0 Hz. Reserpine was injected at 1 mg/kg ip. 
(A) LF/HF response to reserpine over time.  
(B) Both wildtypes and knockouts had a significant drop in LF/HF ratio in 
response to reserpine (*p≤0.05 by paired t-test, n=8). 
(C) Knockouts had a significantly greater relative decrease in LF/HF ratio in 
response to reserpine than wildtypes (*p≤0.05 by t-test, n=8).  
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Figure 4.8. Heart rate variability (HRV) responses to atropine in 
conscious Gnasxl knockout mice.  
Heart rate was recorded from conscious Gnasxl knockout mice and wildtype 
siblings at high resolution (within 0.2 ms). FFT spectra were produced from 
3-minute sections of clean and stable heart rate resampled at 20 Hz using 
Welch’s algorithm with 32-second windows with 50 % overlap. HF power was 
used as an indicator of parasympathetic stimulation of the cardiovascular 
system, and was calculated between 1.0 and 5.0 Hz. Atropine was injected 
at 2 mg/kg ip. 
(A) Response in HF power to atropine over time.  
(B) Both wildtypes and knockouts had a significant drop in HF power after 
atropine injection (*p≤0.05 by paired t-test, n=6).  
(C) Both wildtypes and knockouts had comparable percentage decreases in 
HF power in response to atropine. 
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4.3.2.3 HRV control at night in conscious Gnasxl knockouts  
HRV parameters were calculated for wildtypes and knockouts during the 5-
hour period between 20:00 and 01:00, as this is when the mice had high 
levels of heart rate and activity (Figure 3.5A/C). A minimum of ten 3-minute 
windows were used for each mouse, and the average value for each 
parameter used as a representative value for that mouse. In this way, 
knockouts were found to have elevated LF/HF ratio at night (Figure 4.9; 1.79 
±0.18 vs 1.23 ±0.14, KO vs WT; p≤0.05 by t-test, n=9/12), as well as trends 
for decreased HF power and increased SDNN and Poincaré SD2. 
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Figure 4.9. Basal heart rate variability (HRV) parameters in Gnasxl 
knockouts at night.  
Heart rate was recorded in adult Gnasxl knockout mice and wildtype siblings. 
A number of HRV parameters were analysed from at least ten 3-minute 
sections of heart rate per mouse. HF power and LF/HF ratio were calculated 
from FFT spectra using banding of LF 0.15-1.0 Hz, HF 1.0-5.0 Hz. SDNN 
and RMSSD are the standard time-domain analyses (standard deviation of 
normal RR intervals and root mean square of successive differences, 
respectively). SD1 and SD2 are the two standard deviation parameters from 
Poincaré plots. LF/HF ratio was significantly increased in KO compared to 
WT (*p≤0.05 by t-test). There are no units for LF/HF; HF power has units of 
ms2/Hz; the rest have units of ms.  
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4.4 Discussion 
In Chapter 3 it was shown that mice lacking XLαs have elevated blood 
pressure and heart rate, likely due to elevated sympathetic stimulation. In 
this chapter support for this finding was sought through the use of HRV 
analysis to probe in more detail the sources of autonomic control of the 
cardiovascular system in Gnasxl knockout mice. In particular the specifics of 
SNS versus PNS stimulation, and how the paradoxic autonomic responses 
from Chapter 3 may have been caused. 
HRV analysis offers additional information concerning cardiovascular control 
than simply investigating blood pressure or heart rate. It has been used 
diagnostically in human patients and as a predictive tool to predict cardiac 
pathology, such as ventricular tachycardia (Huikuri et al., 1993).  
HRV has also been used extensively in research to investigate 
cardiovascular control in rodents, but the parameters used for HRV in mice 
are less certain than in humans (Gehrmann et al., 2000). A wide range of 
methodologies are used in the literature, so in order to use HRV analysis in 
this investigation the different HRV methods first had to be validated to 
provide valid and reliable outcomes.  
Firstly two time-domain HRV parameters were investigated: the standard 
deviation of normal RR intervals (SDNN), and the root mean square of 
successive differences (RMSSD). These parameters are the simplest to 
calculate, but can still provide information on autonomic control. SDNN is 
simply a measure of the deviation of a heart rate series over time. It 
increases in line with heart rate “drift” over time, thereby providing a rough 
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estimate of the degree of long-term (or low frequency) variation in heart rate, 
which corresponds mainly to sympathetic stimulation of the cardiovascular 
system. The typical examples in Figure 4.2A demonstrate that SDNN 
decreases after inhibition of the SNS due to reserpine injection.  
RMSSD, on the other hand, roughly quantifies beat-to-beat variation in heart 
rate, thereby giving a crude estimate of the short-term (or high frequency) 
variation in heart rate, which would be expected to more closely correspond 
to parasympathetic stimulation of the cardiovascular system. The typical 
examples in Figure 4.2A demonstrate that RMSSD decreases significantly 
after loss of parasympathetic inhibition by atropine, but there is little effect of 
reserpine injection. These effects were seen consistently across a sample of 
wildtype mice (Figure 4.2B/C), except that there was a non-significant 
decrease in SDNN after atropine injection, which might result in skewed 
quantification of the SNS.  
Secondly nonlinear HRV analysis with Poincaré plots was investigated. This 
is essentially a different (and possibly more robust) method of investigating 
the short- and long-term changes in heart rate variation (Deepak, 2011). The 
corresponding parameters from a Poincaré plot are SD1, which quantifies 
short-term heart rate variation, and SD2, which quantifies long -term heart 
rate variation (Figure 4.3Ai for a typical Poincaré plot).  
Loss of sympathetic stimulation of the cardiovascular system after reserpine 
injection resulted in a reduction in SD2 on the Poincare plot, while SD1 
remained high (Figure 4.3Aii). On the other hand, loss of parasympathetic 
stimulation after atropine injection resulted in a reduction in SD1, while SD2 
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remained high (Figure 4.3Aiii). These effects were seen consistently across a 
sample of wildtype mice (Figure 4.3B/C), except that there was a non-
significant decrease in SD2 after atropine, which might result in skewed 
quantification of the SNS, as with the SDNN. 
Thirdly frequency-domain HRV analyses were investigated using fast Fourier 
transforms (FFTs), as well as both autoregressive and Lomb power spectra. 
Lomb spectra have the added benefit that they function on unevenly spaced 
data, which means that the heart rate series doesn’t need to be resampled 
(Lomb, 1976; Moody, 1993).  
Frequency domain HRV analyses can provide the most information about 
heart rate variability, but require more support and validation from 
experiment. Briefly, power spectra use complex mathematical algorithms to 
quantify the degree of variability in heart rate that is contributed by different 
frequencies in variation. Hence, the total power of an FFT spectrum is 
directly proportional to the standard deviation of the time series analysed, 
split into frequency components.  
Previous studies have attempted to standardise the parameters used to 
define the LF and HF bands of power spectra in mice (Thireau et al., 2008), 
however there is by no means any consensus among different researchers. 
Therefore, typical bandings were used as a guide, but empirical validation 
was required to define the parameters used in this study.  
Having tested and validated various HRV analyses, it was found that all three 
types of power spectra produced valid responses to both reserpine and 
atropine (Figures 4.4-6). However, the autoregressive spectra had a  
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decrease in LF/HF ratio after atropine that approached significance (Figure 
4.5C; 1.4 ±0.2 to 0.9 ±0.2 ms2/Hz; p=0.085 by paired t-test, n=6).  Therefore, 
and additionally due to the difficulty producing Lomb spectra and the 
widespread use of FFT’s in the literature, FFT power spectra were used to 
analyse HRV in the Gnasxl knockout mouse.  
Firstly, the LF/HF ratio was used as a marker of sympathovagal balance; 
LF/HF ratio was significantly reduced after reserpine injection in both 
wildtypes and knockouts (Figure 4.7B), but knockouts had a significantly 
greater % decrease in LF/HF ratio (Figure 4.7C). This confirms that the 
elevated blood pressure and heart rate in Gnasxl knockouts shown in the 
previous chapter is not caused by peripheral effects, such as different 
vascular properties or receptor density (Young & Davisson, 2011), but is in 
fact caused by elevated SNS stimulation of the cardiovascular system.  
The parasympathetic contribution to HRV in the Gnasxl knockout mouse was 
evaluated by HF power response to atropine injection. Atropine caused a 
significant decrease in HF power in both wildtypes and knockouts that was 
consistent between genotypes (Figure 4.8B). This might seem 
counterintuitive in light of the elevated heart rate response to atropine in the 
knockouts, but in fact this could shed light on the mechanism involved: that 
after loss of PNS stimulation in the knockouts, the elevated SNS activity in 
these animals would be more prominent, resulting in a reflex increase in 
cardiovascular output. 
The results so far have shown that Gnasxl knockout mice have elevated 
SNS stimulation of the cardiovascular system, but the PNS seems 
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unaffected. However, these results only reflect the day period, when the mice 
are less active, as this is the time when the injections were performed.  
Therefore, basal levels of autonomic stimulation were investigated during the 
active night period, when Gnasxl knockouts were found to have significantly 
elevated LF/HF as well as a trend for decreased HF power (Figure 4.9). This 
suggests that the knockouts might have consistently higher SNS activity at 
night, and it could be interesting to pursue this result by injection of reserpine 
and atropine during the night and investigating cardiovascular and HRV 
responses. The knockouts also had a trend for increased SDNN and 
Poincaré SD2, which would also correlate with elevated SNS stimulation of 
the cardiovascular system. 
In summary, the HRV changes in Gnasxl knockout mice support the results 
from chapter 3 showing that Gnasxl knockouts have elevated sympathetic 
stimulation of the cardiovascular system, and confirm that this is due to a 
central effect changing SNS activity. This suggests that XLαs normally 
inhibits central control of SNS activity, and therefore lack of XLαs increases 
basal SNS stimulation of the cardiovascular system. 
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5 Investigating XLαs signalling 
pathways mediating cardiovascular 
control 
5.1 Introduction 
XLαs is a signalling protein known to control metabolism via the sympathetic 
nervous system (SNS) (Xie et al., 2006), and is expressed in a number of 
key brain regions involved in SNS control (Krechowec et al., 2012). However, 
arguably the most challenging aspect of investigating XLαs signalling is the 
lack of known signalling partner.  
It is known where XLαs is expressed, and the likely downstream signalling 
(ie. via adenylate cyclase), but it is unknown which receptor(s) it might 
couple to in vivo. This question has been previously addressed with 
respected to location (ie. a signalling partner for XLαs must be expressed in 
the same cell (Krechowec et al., 2012)), but co-staining XLαs with known 
GPCRs in the brain has elicited little success.  
5.1.1 XLαs signalling 
A number of studies have investigated the role of XLαs signalling in vitro , 
which have shown that XLαs is potentially capable of coupling to a few 
known GPCRs, including β2-AR and PTHR (Liu et al., 2011). However, there 
is no known Gsα-coupled GPCR that gives a lean phenotype similar to XLαs 
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when mutated, therefore there are no viable options for possible XLαs 
signalling partners among known GPCRs.  
In this chapter, the approach used is to test the response to agonists of 
neuronal receptors of interest. This experiment is limited to choosing known 
GPCRs with known agonists, which are unlikely to couple directly to XLαs. Of 
particular interest is the response of the melanocortin pathway, which has 
such a profound effect on energy balance, and has been investigated in 
detail with respect to Gsα coupling.  
5.1.2 Melanocortin pathways 
The melanocortin system is a well known mediator of food intake, 
metabolism and SNS control of the cardiovascular system (Balthasar et al., 
2005), and was interesting to investigate. It has been shown previously that 
the MC4R couples via Gsα (Chen et al., 2009). However, the situation 
remains unclear, particularly in the PVN, where Gsα control the 
cardiovascular system, but MC4R is known to have potent effects on energy 
expenditure (Chen et al., 2011).  
In this study, the MC4R pathway will be investigated by ICV injection of the 
classic melanocortin agonist melanotan II (MTII) (Irani & Haskell-Luevano, 
2005), recording blood pressure and heart rate responses. MC4R signalling 
will also be investigated in conscious mice by ip injection, and using 
electrocardiogram (ECG) telemeters to record heart rate.  
For peripheral injections, MTII could not be used, as it activates MC3R as 
well as MC4R, and would therefore cause off-target peripheral effects; for 
Chapter 5: Cardiovascular control by XLαs signalling pathways  
118 
 
example, MC3Rs are found on the heart (Chhajlani, 1996), and MTII will 
therefore have direct cardiac effects if injected peripherally. Therefore, the 
agonist Ro27-3225 was used, as this has been shown to cause central 
activation of MC4R when injected peripherally, and has 100-fold higher 
affinity for MC4R than the MC3R (Benoit et al., 2000). 
5.1.3 GLP-1 pathways 
The other pathway tested was the glucagon-like peptide 1 (GLP-1) signalling 
pathway. GLP-1 is an incretin hormone, which signals peripherally to control 
insulin signalling and glucose homeostasis (Holst, 2007). However, a 
separate GLP-1 signalling system is also found in the brain, where GLP1 
acts as a peptide neurotransmitter to control food intake, metabolism and the 
cardiovascular system (Yamamoto et al., 2002; Baggio et al., 2004).  
Additionally, the expression pattern of the GLP-1 receptor closely mirrors that 
of XLαs, including the medullary raphe nuclei and the hypothalamic PVN 
(Merchenthaler et al., 1999), making it a likely candidate for involvement in 
XLαs signalling. Peripheral injection of Exendin-4, a protease-resistant GLP1 
analogue, has been shown to activate central GLP-1 receptors and result in 
increase SNS activity, causing elevated blood pressure and heart rate 
(Yamamoto et al., 2002). 
The doses used for all three of these drugs are taken from the literature, with 
the aim of producing a robust cardiovascular response. For central injections, 
mice were anaesthetised urethane-chloralose and drugs were injected ICV; 
blood pressure and heart rate responses were recorded. For peripheral 
injections, ECG telemetry was used; heart rate responses were recorded, 
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and for more information about the response to Exendin-4, heart rate 
variability (HRV) was investigated by fast Fourier transform (FFT) power 
spectral analysis.  
5.1.4 Aims 
The aim of this chapter is to use cardiovascular responses to investigate how 
loss of XLαs might impact on known neuropeptide signalling pathways; 
specifically, it is likely that Gnasxl knockouts will be sensitive to pathways 
that stimulate the SNS. The outcome of this experiment might afford the first 
indication of how XLαs signalling might mediate its effects in mice, and 
provide a stepping stone for further investigations into the mechanism of 
XLαs function in the mouse. Three techniques will be used to achieve this: 
blood pressure recording in anaesthetised mice with ICV injection; heart rate 
recording in conscious mice with ip injection; and finally HRV analysis in 
conscious mice with ip injection. 
5.2 Methods 
Adult male Gnasxlm+p- knockout mice and wildtype siblings were used for this 
experiment. Cardiovascular recordings were performed , as described in 
chapter 2, by ECG telemetry in conscious mice and by arterial cannulation in 
urethane-chloralose anaesthetised mice. Blood pressure, heart rate and 
heart rate variability were analysed as described in chapters 2-4.  
Anaesthetised mice were injected ICV with 0.5 µg Exendin-4 or 600 pmol 
MTII in 1 µl volume, dissolved in aCSF. The coordinates for ICV injections 
were calculated from Paxinos and Franklin (Paxinos & Franklin, 2001), 
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according to the following distances from Bregma: 0.2mm caudal, 1.0 mm 
lateral and 3.7 mm vertical from the surface of the skull. At the end of the 
experiment 1 µl of 1 % (w/v) Chicago Blue (Sigma) was injected at the same 
coordinates to confirm correct injection.   
Conscious mice were injected intraperitoneally with sterile 0.9 % saline, 1 
µg/kg and 50 µg/kg Exendin-4, or they were injected intravenously (tail vein) 
with 0.9 % saline and 50 µg/kg Ro27-3225. All drugs were diluted according 
to body weight into sterile 0.9 % saline and injected in 50 µl volume. If mice 
were given multiple drug injections, at least two days were left between each 
to allow the previous drug to be metabolised and excreted.  
5.3 Results 
5.3.1 Control of melanocortin signalling in Gnasxl knockout mice  
The role of melanocortin signalling in cardiovascular control in Gnasxl  
knockouts was investigated by ICV injection of MTII in anaesthetised Gnasxl  
knockout mice, recording blood pressure and heart rate responses. Further 
investigations were performed by ip injection of the MC4R agonist Ro27-
3225 in conscious Gnasxl knockout mice, recording heart rate responses. 
5.3.1.1 Blood pressure and heart rate responses to central MTII 
injection in anaesthetised Gnasxl knockout mice 
The classic melanocortin agonist MTII was injected ICV in anaesthetised, 
cannulated adult mice. MTII was expected to increased blood pressure and 
heart rate via activation of the SNS (Haynes et al., 1999). Typical blood 
pressure responses to 600 pmol MTII ICV are shown in Figure 5.1A for 
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wildtype (top) and knockout (bottom). Both show clear blood pressure 
responses within a couple of minutes of injection.  
However, the blood pressure change is not so clear when averaged over 
time for a sample of animals, as shown in Figure 5.1B. Linear trendlines for 
BP before and after injection (Figure 5.1C) show that blood pressure is on a 
steady decline before injection. The trend lines show that, at least in 
knockouts, there appears to be a change in the general decrease in BP over 
time. However, no significant BP responses could be quantified due to the 
downward trend and the high variability in response between subjects.  
There was a general increase in average heart rate after MTII injection for 
both wildtype and knockout (Figure 5.2A). However, mean heart rate was 
only significantly increased in knockout (Figure 5.2B; 612 ±45 to 651 ±39 
bpm, p≤0.05 by paired t-test, n=6), but not in wildtype mice (Figure 5.2B; 597 
±40 to 616 ±30 bpm, n=5). There was no significant difference in heart rate 
change between wildtype and knockout mice (Figure 5.2C; 39 ±10 vs 19 ±9 
bpm, KO vs WT; n=6/5). 
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Figure 5.1. Blood pressure responses to central MTII in anaesthetised 
Gnasxl knockout mice.  
Blood pressure was recorded from urethane-chloralose anaesthetised 
Gnasxl knockout mice and wildtype siblings. The melanocortin MC3/4R 
agonist MTII was injected ICV at 600pmol in aCSF. 
(A) Typical traces of blood pressure responses to MTII in WT (top) and KO 
(bottom).  
(B) Mean blood pressure responses over time.  
(C) Linear regression lines of blood pressure responses for WT (solid line) 
and KO (dashed line). 
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Figure 5.2. Heart rate responses to central MTII in anaesthetised Gnasxl 
knockout mice.  
Heart rate was recorded from urethane-chloralose anaesthetised Gnasxl  
knockout mice and wildtype siblings. The melanocortin MC3/4R agonist MTII 
was injected ICV at 600pmol in aCSF. 
(A) Average heart rate response over time for Gnasxl knockouts and 
wildtype siblings.  
(B) Heart rate was significantly increased in knockouts but not in wildtypes 
(*p≤0.05 by paired t-test, n=6).  
(C) There was no significant difference in average heart rate change 
between wildtypes and knockouts. 
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5.3.1.2 Heart rate responses to peripheral Ro27-3225 injection in 
conscious Gnasxl knockout mice 
The synthetic melanocortin agonist Ro27-3225 was injected peripherally at a 
dose of 50 µg/kg. However, there was no obvious change in heart rate in 
wildtypes or knockouts, other than the usual increase due to handling stress 
(Figure 5.3A). On average, heart rate remained constant in both wildtypes 
(Figure 5.3B; 577 ±90 to 572 ±63 bpm; n=4) and in knockouts (Figure 5.3B; 
597 ±34 to 559 ±34 bpm; n=3) after injection of Ro27-3225, and there was 
no significant difference in response between the two (Figure 5.3C; -14 ±67 
vs -5 ±85 bpm, KO vs WT; n=3/4). The lack of effect is possibly due to 
difficulties in performing the tail vein injections, which stress the mice more 
than usual, and it is not always possible to inject the full dose of drug.  
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Figure 5.3. Heart rate response to Ro27-3225 in conscious Gnasxl 
knockout mice.  
Heart rate was recorded using ECG telemetry from conscious Gnasxl  
knockout mice and wildtype siblings. The melanocortin MC4R-specific 
agonist Ro27-3225 was injected at 50 µg/kg iv.  
(A) Heart rate response to Ro27-3225 over time.  
(B) Mean heart rate before and after Ro27-3225.  
(C) Both wildtypes and knockouts had no change in heart rate in response to 
Ro27-3225. 
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5.3.2 Control of GLP-1 signalling in Gnasxl knockout mice 
The role of glucagon-like peptide 1 (GLP-1) signalling in cardiovascular 
control in Gnasxl knockouts was investigated by ICV injection of the GLP-1 
receptor agonist Exendin-4 in to anaesthetised Gnasxl knockout mice, 
recording blood pressure and heart rate responses. Further investigations 
were performed by ip injection of the Exendin-4 in conscious Gnasxl  
knockout mice, recording heart rate responses, as well as HRV analysis 
using FFT spectra to investigate the specific contribution of the sympathetic 
and parasympathetic branches of the autonomic nervous system.  
5.3.2.1 Blood pressure and heart rate responses to central Exendin-4 
injection in anaesthetised Gnasxl knockout mice 
Exendin-4 was injected ICV in anaesthetised, cannulated adult mice, at a 
dose of 0.5 µg. Typical blood pressure responses to 0.5 µg Exendin-4 ICV 
are shown in Figure 5.4A for wildtype (top) and knockout (bottom). Both 
show clear blood pressure responses within a couple of minutes of injection. 
However, the blood pressure change is not so clear when averaged over 
time, as shown in Figure 5.4B. Linear trendlines for BP before and after 
injection (Figure 5.4C) show that blood pressure is on a steady decline 
before injection. However, no objective BP responses could be quantified 
due to the downward trend and the high variability in response between 
subjects. After injection, there appears to be a decrease in the BP decline 
over time, but there is no way of distinguishing between wildtype and 
knockout mice.  
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There was a general increase in average heart rate after ICV Exendin-4 
injection for both wildtype and knockout (Figure 5.5A). Mean heart rate was 
significantly increased in knockout after ICV Exendin-4 (Figure 5.5B; 615 ±9 
to 633 ±6 bpm, p≤0.05 by paired t-test n=8), but not in wildtype (Figure 5.5B; 
557 ±29 to 585 ±38 bpm, n=6). There was no significant difference in heart 
rate change between wildtype and knockout (Figure 5.5C). 
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Figure 5.4. Blood pressure responses to central Exendin-4 in 
anaesthetised Gnasxl knockout mice.  
Blood pressure was recorded from urethane-chloralose anaesthetised 
Gnasxl knockout mice and wildtype siblings. The protease-resistant GLP1R 
agonist Exendin-4 was injected ICV at 500ng in aCSF.  
(A) Typical traces of blood pressure responses to Exendin-4 in WT (top) and 
KO (bottom).  
(B) Mean blood pressure responses over time. 
(C) Linear regression lines of blood pressure responses for WT (solid line) 
and KO (dashed line). 
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Figure 5.5. Heart rate responses to central Exendin-4 in anaesthetised 
Gnasxl knockout mice.  
The protease-resistant GLP1R agonist Exendin-4 was injected 500ng ICV 
into urethane-chloralose anaesthetised Gnasxl knockout mice and wildtype 
siblings.  
(A) Average heart rate response over time for Gnasxl knockouts and 
wildtype siblings.  
(B) Heart rate was significantly increased in knockouts but not in wildtypes 
(*p≤0.05 by paired t-test).  
(C) There was no difference in average heart rate change between wildtypes 
and knockouts. 
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5.3.2.2 Heart rate responses to peripheral Exendin-4 injection in 
conscious Gnasxl knockout mice 
Exendin-4 is a protease-resistant analogue of GLP1, which is reported to 
cross the BBB and activate central SNS control of the cardiovascular system 
following peripheral injection. Exendin-4 was injected at 1 µg/kg, which is a 
low dose as in (Yamamoto et al., 2002), but little lasting effect was seen in 
either wildtype or knockout (Figure 5.6A). We then injected Exendin-4 at 50 
µg/kg, similar to (Sowden et al., 2007) or a high dose in (Yamamoto et al., 
2002), which produced a sustained HR increase in knockout (Figure 5.6B; 
p≤0.05, n=7) but not wildtype mice (Figure 5.6B; n=7). 50 µg/kg Exendin-4 
produced a significantly greater HR increase in knockout than in wildtype 
mice (Figure 5.6C; 72 ±23 vs 12 ±20 bpm in KO vs WT, p≤0.05 by t-test). 
This was further investigated by HRV analysis to probe the specific changes 
in autonomic control that caused the hypersensitivity response to Exendin-4 
in Gnasxl knockout mice.  
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Figure 5.6. Heart rate responses to Exendin-4 in conscious Gnasxl 
knockout mice.  
The protease-resistant GLP1R agonist Exendin-4 was injected 1µg/kg and 
50µg/kg ip into conscious Gnasxl knockout mice and wildtype siblings.  
(A) (i) Heart rate response to Exendin-4 over time at 1µg/kg, and (ii) average 
heart rates.  
(B) (i) Heart rate response to Exendin-4 over time at 50µg/kg, and (ii) 
average heart rates; heart rate is significantly elevated in knockouts after 
50µg/kg Exendin-4 (**p≤0.01 by paired t-test, n=7).  
(C) Heart rate change in wildtypes and knockouts in response to Exendin-4 
50µg/kg.  
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5.3.2.3 Heart rate variability responses to peripheral Exendin-4 
injection in conscious Gnasxl knockout mice 
Firstly, the sympathetic HRV responses were investigated as the LF/HF ratio  
from FFT spectra, which didn’t change noticeably after injection (Figure 
5.7A). This was supported by quantification of the LF/HF ratio before and 
after Exendin-4 injection (Figure 5.7B), and there was no difference in 
percentage change compared to saline (Figure 5.7C).  
Secondly, the parasympathetic HRV responses were investigated as the 
change in HF power from FFT spectra. HF power was dramatically reduced 
in wildtype and knockout following Exendin-4 injection (Figure 5.8A). This 
was a significant change in wildtype mice (Figure 5.8B; 6.3 ±2.3 to 1.4 ±0.4 
ms2/Hz; p≤0.05 by paired t-test, n=7), but not in knockout mice due to high 
variability in the starting HF power.  
However, when compared as percentage change in HF power after Exendin-
4 injection, both wildtype and knockout had a highly significant percentage 
decrease in HF power (Figure 5.8C; -76 ±4 and -77 ±9 % for WT and KO; 
p≤0.001 by paired t-test, n=7/7), with no difference between the two. 
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Figure 5.7. Sympathetic-mediated HRV responses to Exendin-4 in 
conscious Gnasxl knockout mice.  
The protease-resistant GLP1R agonist Exendin-4 was injected 50µg/kg ip 
into conscious Gnasxl knockout mice and wildtype siblings.  
(A) LF/HF ratio response to Exendin-4 over time; boxes show regions 
averaged in (B).  
(B) Mean LF/HF before and after Exendin-4 in wildtypes and knockouts.  
(C) Mean percentage changes to LF/HF in response to Exendin-4 in 
wildtypes and knockouts. 
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Figure 5.8. High frequency HRV responses to Exendin-4 in conscious 
Gnasxl knockout mice.  
The protease-resistant GLP1R agonist Exendin-4 was injected 50µg/kg ip 
into conscious Gnasxl knockout mice and wildtype siblings.  
(A) HF power response to Exendin-4 over time; boxes show regions 
averaged in (B).  
(B) Mean HF power before and after Exendin-4 in wildtypes and knockouts.  
(C) Both wildtypes and knockouts have a significant % decrease in HF power 
(***p≤0.001 by paired t-test, n=7). 
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5.4 Discussion 
The aim of this chapter was to investigate neuronal signalling pathways that 
might be disrupted in Gnasxlm+p- knockout mice. Cardiovascular responses 
were recorded to agonists for the central melanocortin receptor MC4R and 
the GLP1 receptor. 
The melanocortin system is a well known mediator of appetite, metabolism 
and the cardiovascular system via control of the SNS (Hall et al., 2010). 
There are numerous members of the melanocortin family of receptors, which 
are expressed in different regions of the body. The main receptor involved in 
SNS control in the brain is the MC4R, and it is this receptor that was 
hypothesised to possibly be deregulated in Gnasxlm+p- knockouts, and 
therefore was the receptor of interest for this investigation. The classic 
MC3/4R agonist MTII was injected ICV, and the blood pressure and heart 
rate responses were recorded.  
Although there were good BP responses to MTII (Figure 5.1A), high 
variability between animals and a declining basal blood pressure meant there 
was no objective way of discerning a significantly different BP response 
between wildtype and knockout mice. However, linear trendlines through the 
average blood pressure showed that there might be a more substantial 
change in the declining BP trend in knockouts than in wildtypes.  
The heart rate responses to MTII were also investigated, which showed a 
much clearer effect than the blood pressure response, and in this case the 
knockouts had a significant increase in heart rate, which was not seen in the 
wildtypes. This result suggests that the knockouts might be sensitive to 
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MC4R signalling, as hypothesised in the introduction. However, due to the 
inconclusive BP response, I wanted to confirm this in conscious mice using 
telemetry.  
For the telemetry experiment an agonist was needed that could be injected 
peripherally but would act centrally to activate specifically the MC4R 
preferentially over the other melanocortin receptors. The synthetic compound 
Ro27-3225 was chosen as an agonist that is specific for the MC4R, and has 
over 100-fold higher affinity for MC4R than MC3R (Benoit et al., 2000).  
Ro27-3225 has also been reported to improve cardiovascular parameters 
when injected peripherally, in this case in response to haemorrhagic shock 
(Giuliani et al., 2007). No direct cardiovascular responses to Ro27-3225 
have been previously reported, so the dose was taken from Giuliani et al. 
where it was injected iv at 54 nmol/kg. This is equivalent to 42.4 µg/kg, so I 
rounded this up to 50 µg/kg. However, the iv injections were technically 
challenging and resulted in ambiguous and inconclusive cardiovascular 
responses (Figure 5.3).  
Exendin-4 is a well-known agonist to the GLP1R, and is in clinical use in 
Type II diabetes to improve glucose metabolism and insulin sensitivity, for 
example as the drug Exenatide (www.byetta.com). Exendin-4 was injected 
ICV in anaesthetised, cannulated adult mice, and blood pressure and heart 
rate responses were recorded.  
However, as with the MTII ICV injections, the baseline blood pressure and 
BP response to Exendin-4 were highly variable, and the baseline BP was 
declining over time, which made it impossible to discern any objective 
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significantly different blood pressure changes (Figure 5.4). Using linear 
trendlines, it was possible to discern an effect on the blood pressure, 
essentially a lessening of the BP decline. However, there was no difference 
between the wildtypes and knockouts.  
Heart rate responses were also investigated (Figure 5.5); heart rate generally 
increased in wildtypes and knockouts, but was only significant in knockouts. 
However, the effect compared to wildtypes was inconclusive, so the 
cardiovascular effects in conscious mice were investigated next.  
 Exendin-4 is widely used as a GLP1R agonist in cardiovascular studies in 
conscious animals, and is reported to cross the BBB (Kastin & Akerstrom, 
2003) and to activate central GLP1 receptors to produce an increase in SNS 
stimulation of peripheral effectors (Nogueiras et al., 2009; Perez-Tilve et al., 
2010). Reports of the use of Exendin-4 in cardiovascular studies varies, so 
we tried two different doses of Exendin-4, as from (Yamamoto et al., 2002; 
Sowden et al., 2007).  
Low dose Exendin-4 produced a trend towards elevated HR in knockout 
compared to wildtype mice (Figure 5.6A); high dose Exendin-4 produced a 
significantly elevated HR in knockout compared to wildtype (Figure 5.6B). 
This was very interesting as it mirrors the elevated cardiovascular response 
to activation of the MC4R in knockouts shown earlier. This suggests that lack 
of XLαs results in hypersensitivity to such SNS-increasing neural pathways.  
To investigate this further, the heart rate variability responses to Exendin-4 
50 µg/kg were investigated, using LF/HF ratio as a marker of sympathetic 
activity, and HF power as a marker of parasympathetic activity. Using these 
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markers, with the same parameters as those defined in chapter 3, no change 
in LF/HF ratio was found in response to Exendin-4, in wildtype or knockout 
(Figure 5.7). This result is contrary to most of the previously published 
studies which show that peripheral Exendin-4 injections causes an increase 
in central SNS control, including elevated sympathetic stimulation of muscle   
(Barrucha et al., 2008) and white adipose tissue (Nogueiras et al., 2009) and 
activation of sympathetic preganglionic neurones of the spinal cord 
(Yamamoto et al., 2002). 
However, Griffioen et al. showed that the cardiovascular effects of peripheral 
Exendin-4 are caused by a decrease in parasympathetic activity, as 
calculated by HRV analysis (Griffioen et al., 2011). This effect was also seen 
here; both wildtype and knockout mice had a highly significant decrease in 
HF power in response to Exendin-4. This suggests that Exendin-4 produces 
a decrease in parasympathetic stimulation of the cardiovascular system.  
This might provide an explanation for the hypersensitive HR response of the 
knockouts for Exendin-4, when the results of chapters 3 and 4 are taken into 
account. In the same way as seen here with Exendin-4, atropine caused an 
equivalent reduction in parasympathetic HRV in wildtypes and knockouts, but 
caused an elevated heart rate response in knockouts. This is interesting 
given that XLαs is expressed in both the NTS and the nucleus ambiguus, the 
main sites for control of PNS output. The involvement of XLαs neurones in 
this Exendin-4 response will be investigated in Chapter 6. 
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6 Investigating the role of XLαs in 
neuronal c-fos responses to 
Exendin-4  
6.1 Introduction 
In the previous chapter it was shown that mice lacking XLαs were  
hypersensitive to Exendin-4, specifically that they had a greater heart rate 
response to Exendin-4. There are a number of ways to further investigate the 
neuronal signalling involved in this interesting result. In this chapter, the 
possible effects of loss o f XLαs to neuronal signalling are investigated by 
immunohistochemistry staining for the early response marker c-fos.  
6.1.1 c-fos 
c-fos is a so-called early response gene that can be used as a useful 
indicator of neuronal activity, for a review of c-fos studies into cardiovascular 
control see Dampney and Horiuchi 2003 (Dampney & Horiuchi, 2003). It 
encodes the transcription factor Fos that is transiently highly expressed in 
response to stimulus (Figure 6.1); in neurones, this is likely to be 
depolarisation of the membrane. Fos, together with its partner Jun, control 
expression of so-called “late-response” genes, such as neurotransmitters. 
  
Chapter 6: Neuronal responses to Exendin-4 in Gnasxl knockouts 
140 
 
 
Figure 6.1. Diagram showing transcription control by Fos. 
A stimulus, for example depolarisation or neurotransmitters in a neurone, 
stimulates transcription of c-fos and c-jun, via 2nd messengers such as Ca2+ 
and GTP. c-fos and c-jun are transcribed to the transcription factors Fos and 
Jun, respectively, which activate transcription of “late-response” genes, such 
as neurotransmitters. Modified from (Dampney & Horiuchi, 2003).  
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6.1.2 Benefits of using c-fos 
There are a number of benefits of using c-fos as a marker of neuronal 
activation (Dampney & Horiuchi, 2003). Briefly, individual neurones can be 
identified by immunohistochemical staining for c-fos, and additionally 
population responses can be quantified. This is better than other techniques 
that typically allow for either population responses or individual responses, 
for example by 2-deoxy-D-glucose uptake or patch clamping, respectively.  
Furthermore, the signal-to-noise ratio is good, as the basal levels of Fos are 
low but become highly expressed in response to stimulus. Fos can be used 
as a response in conscious mice; in fact, anaesthetics can reportedly cause 
high levels of background (Dampney et al., 1995), so responses in conscious 
mice are preferable. Finally, and arguably the most significant benefit, is that 
it is possible to co-stain Fos against markers of neuronal cell types, for 
example it is possible to quantify neuronal responses in only 
catecholaminergic neurones (Yamamoto et al., 2002).  
6.1.3 Limitations of using c-fos 
There are however a number of limitations to using Fos quantification. Not all 
neurones respond equally to stimulus, for example neurones in the 
substantia nigra apparently do not produce Fos at all (Dragunow & Faull, 
1989). Additionally, strong and sustained stimulation of the neurone is 
required to produce a Fos response, which has a number of implications.  
Firstly, it is possible that particular neurones are involved in a response, but 
the stimulus wasn’t sustained enough to produce a Fos response. Secondly, 
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the hierarchy of response becomes unclear; it becomes challenging to 
differentiate between primary or secondary order neurones. Thirdly, the 
source of stimulus is unclear, for example because of converging pathways. 
A number of early-response genes have been investigated in this capacity, 
but Fos has been shown to provide the most reliable response (Lanteri-Minet 
et al., 1994). 
6.1.4 c-fos studies involving Exendin-4 
A number of studies have investigated the c-fos responses to Exendin-4. 
Yamamoto et al. investigated the cardiovascular as well as neuronal c-fos 
responses to Exendin-4 (Yamamoto et al., 2002). They showed that both 
peripheral and central injections of Exendin-4 caused a significant increase 
in blood pressure and heart rate in rats. They proceeded to investigate the c-
fos responses to Exendin-4, and found that peripherally and centrally 
injected Exendin-4 resulted in similar activation of a number of brain regions  
involved in autonomic control, including the PVN, LC, NTS and AP, and the 
ventrolateral medulla (CVLM and RVLM).  
Further investigations showed that Exendin-4 activated, among others, 
spinally-projecting catecholaminergic neurones of the medulla. Studies have 
since confirmed the overall c-fos results, particularly showing that the PVN, 
NTS and AP consistently respond to Exendin-4 (Baggio et al., 2004; Baraboi 
et al., 2011).   
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6.1.5 Aims 
The aim of this chapter is to use Fos immunostaining to investigate neuronal 
activation in response to Exendin-4 with respect to absence of XLαs, 
focussing on the nucleus of the solitary tract (NTS) and area postrema (AP) 
in the hindbrain, and the paraventricular nucleus (PVN) and amygdala of the 
hypothalamus. It is expected that Gnasxl knockouts will have a greater 
neuronal response, particularly in regions crucial for SNS control such as the 
PVN. The c-fos responses specifically in XLαs-expressing neurones will also 
be investigated, in order to determine the involvement of XLαs in the 
hypersensitive heart rate response to Exendin-4. 
6.2 Methods 
Adult male Gnasxlm+p- knockout mice and wildtype siblings were injected ip 
with 50 µg/kg Exendin-4. 2 hours after injection, mice were terminally 
anaesthetised with pentobarbitone and then perfused with 4 % PFA. The 
brains were carefully removed and placed in 4 % PFA overnight at 4 °C then 
dehydrated in 30 % sucrose solution at 4 °C until they were cut on a cryostat 
to 12 µm. Sections were stored at -80 °C until use. To investigate the global 
change in number of c-fos responsive neurones, c-fos was stained by 
immunohistochemistry using low concentration 1° antibody Rabbit α c-fos 
(1:50k) and Vectastain biotinylated secondary antibody. This method was 
used to give strong staining (Vectastain) only in neurones that express high 
levels of c-fos (1:50k 1°). Numbers of c-fos positive nuclei were counted from 
2-3 sections per regions, and quantified as numbers of positive cells per 
section per side.  
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c-fos responses in specific populations of neurones were investigated using 
immunofluorescence with higher concentration of 1° Rabbit α c-fos (1:2000) 
costained with Goat α XLαs (in wildtype mice only). Further details of all 
protocols can be found in Chapter 2. 
6.3 Results 
6.3.1 c-fos responses to Exendin-4 in Gnasxl knockout mice 
c-fos responses to 50 µg/kg Exendin-4 were quantified by 
immunohistochemistry staining in Gnasxl knockouts and wildtype siblings.  
6.3.1.1 Hindbrain c-fos responses   
High levels of c-fos response were seen in both the area postrema (AP) and 
the medial nucleus of the solitary tract (mNTS), at approximately 7.6 mm 
caudal to Bregma, according to (Paxinos & Franklin, 2001). Typical c-fos 
responses to Exendin-4 for a wildtype and a knockout are shown in Figure 
6.2A. There were no c-fos responses in response to saline (Figure 6.2B). 
Numbers of c-fos positive nuclei were quantified, and no significant 
difference was found between wildtypes and knockouts in either the mNTS 
(Figure 6.2C; 43 ±7 vs 30±9, WT vs KO, n=5) or the AP (Figure 6.2C; 26 ±3 
vs 23 ±6, WT vs KO, n=5). 
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Figure 6.2. c-fos responses to Exendin-4 in the NTS and area postrema. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
Gnasxl knockouts and wildtype siblings.  
(A) Typical c-fos responses in wildtypes (WT) and knockouts (KO) in 
response to Exendin-4, at 7.6 mm  caudal to bregma, according to (Paxinos 
& Franklin, 2001).  
(B) Control stainings showing no c-fos responses to saline in WT or KO.  
(C) Average c-fos counts for the nucleus of the solitary tract (NTS) and the 
area postrema (AP) around the coordinates shown.  
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6.3.1.2 Hypothalamic c-fos responses 
High levels of c-fos response were seen in the paraventricular nucleus 
(PVN), at approximately 0.8 mm caudal to Bregma, according to (Paxinos & 
Franklin, 2001). Typical responses to Exendin-4 for a wildtype and a 
knockout are shown in Figure 6.3A. There were no c-fos responses in 
response to saline (Figure 6.3B). Numbers of c-fos positive nuclei were 
quantified, and no significant difference was found between wildtypes and 
knockouts (Figure 6.3C; 46 ±21 vs 37 ±8, WT vs KO, n=5). 
The amygdala also showed distinctive c-fos responses, at approximately 0.9 
mm caudal to Bregma, according to (Paxinos & Franklin, 2001). Typical 
responses to Exendin-4 for a wildtype and a knockout are shown in Figure 
6.4A. There were no c-fos responses in response to saline (Figure 6.4B). 
Numbers of c-fos positive nuclei were quantified, and no significant 
difference was found between wildtypes and knockouts (Figure 6.4C; 24 ±8 
vs 24 ±6, WT vs KO, n=5). 
  
Chapter 6: Neuronal responses to Exendin-4 in Gnasxl knockouts 
147 
 
 
Figure 6.3. c-fos responses to Exendin-4 in the PVN. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
Gnasxl knockouts and wildtype siblings.  
(A) Typical c-fos responses in wildtypes (WT) and knockouts (KO) in 
response to Exendin-4, at 0.8 mm  caudal to bregma, according to (Paxinos 
& Franklin, 2001).  
(B) Control stainings showing no c-fos responses to saline in WT or KO. 
(C) Average c-fos counts for the paraventricular nucleus (PVN) around the 
coordinates shown. 
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Figure 6.4. c-fos responses to Exendin-4 in the amygdala. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
Gnasxl knockouts and wildtype siblings.  
(A) Typical c-fos responses in wildtypes (WT) and knockouts (KO) in 
response to Exendin-4, at 0.9 mm  caudal to bregma, according to (Paxinos 
& Franklin, 2001).  
(B) Control stainings showing no c-fos responses to saline in WT or KO. 
(C) Average c-fos counts for the amygdala around the coordinates shown.  
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6.3.2 c-fos responses to Exendin-4 in XLαs-expressing neurones 
c-fos responses to 50 µg/kg Exendin-4 were quantified by 
immunofluorescence (IF) co-staining against XLαs. 
6.3.2.1 Hindbrain c-fos responses in XLαs neurones   
IF co-staining in the AP at approximately the same region as shown in the 
IHC staining showed that there were some c-fos positive XLαs neurones 
(Figure 6.5A). At the same caudal location, in the mNTS where there were 
many c-fos positive neurones and few XLαs-positive neurones, many of the 
XLαs neurones were positive for c-fos (Figure 6.6). However, more anterior 
in the NTS, at approximately 6.8 mm caudal to Bregma, where the majority 
of the XLαs-positive neurones of the NTS are to be found, there were few c -
fos positive neurones, and no double positive cells (Figure 6.7).  
6.3.2.2 Hypothalamic c-fos responses in XLαs neurones 
There was a very interesting pattern in the PVN, where the XLαs -positive 
neurones are found around the periphery of the nucleus, and all the c-fos 
positive cells were found in the central area of the PVN (Figure 6.8A). In fact 
there was such a distinction in the populations of neurones that despite there 
being a large number of both there were no XLαs neurones positive for c-fos. 
This was also true in the amygdala, although there were fewer numbers of 
positive cells in this area (Figure 6.9A). 
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Figure 6.5. c-fos responses to Exendin-4 in XLαs-expressing neurones 
of the area postrema. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
XLαs-expressing neurones.  
(A) Typical c-fos response in the area postrema (AP) of a wildtype mouse, 
showing XLαs-expressing neurones (red), c-fos (green) and the nuclear stain 
DAPI (blue). Green arrow, neurone expressing c-fos; red arrow, neurone 
expressing XLαs; white arrow, neurone co-expressing c-fos and XLαs. 
(B) Typical c-fos response in the same region of the AP in a Gnasxl knockout 
mouse, showing c-fos responses but no XLαs staining.  
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Figure 6.6. c-fos responses to Exendin-4 in XLαs-expressing neurones 
of the medial NTS. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
XLαs-expressing neurones. Typical c-fos response in the medial region of 
the nucleus of the solitary tract (NTS) of a wildtype mouse, at approximately 
7.6 mm caudal to Bregma according to (Paxinos & Franklin, 2001). Staining 
shows XLαs-expressing neurones (red), c-fos (green) and the nuclear stain 
DAPI (blue). Green arrow, neurone expressing c-fos; white arrow, neurone 
co-expressing c-fos and XLαs. 
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Figure 6.7. c-fos responses to Exendin-4 in XLαs-expressing neurones 
of the anterior NTS. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
XLαs-expressing neurones. Typical c-fos response in the anterior region of 
the nucleus of the solitary tract (NTS) of a wildtype mouse, at approximately 
6.8 mm caudal to Bregma according to (Paxinos & Franklin, 2001). Staining 
shows XLαs-expressing neurones (red), c-fos (green) and the nuclear stain 
DAPI (blue). Green arrow, neurone expressing c-fos; red arrow, neurone 
expressing XLαs.  
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Figure 6.8. c-fos responses to Exendin-4 in XLαs-expressing neurones 
of the PVN. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
XLαs-expressing neurones.  
(A) Typical c-fos response in the paraventricular nucleus of the 
hypothalamus (PVN) of a wildtype mouse, showing XLαs-expressing 
neurones (red), c-fos (green) and the nuclear stain DAPI (blue).   
(B) Typical c-fos response in the same region of the PVN in a Gnasxl  
knockout mouse, showing c-fos responses but no XLαs staining.  
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Figure 6.9. c-fos responses to Exendin-4 in XLαs-expressing neurones 
of the amygdala. 
Neuronal c-fos responses 2 hours after injection of 50 µg/kg Exendin-4 ip in 
XLαs-expressing neurones. 
(A) Typical c-fos response in the amygdala of a wildtype mouse, showing 
XLαs-expressing neurones (red), c-fos (green) and the nuclear stain DAPI 
(blue). Green arrow, neurone expressing c-fos; red arrow, neurone 
expressing XLαs. 
(B) Typical c-fos response in the same region of the amygdala in a Gnasxl  
knockout mouse, showing c-fos responses but no XLαs staining.  
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6.4 Discussion 
A number of previous studies have shown that peripheral injection of 
Exendin-4 consistently induces a c-fos response in a number of nuclei critical 
in the integration and control of SNS signalling, including the AP and NTS in 
the hindbrain, and the PVN and amygdala in the hypothalamus (Yamamoto 
et al., 2002; Baggio et al., 2004; Baraboi et al., 2011). Robust c-fos 
responses were seen in all these nuclei in this study, with little difference in 
overall numbers of activated neurones between Gnasxl knockouts and 
wildtype siblings, except in the mNTS where there was a definite trend for a 
decrease in activated neurones in the knockouts  (Figures 6.2-4). This is 
interesting in light of the hypersensitive cardiovascular response to Exendin-
4 seen in the knockouts in Chapter 5, as one might expect an increase in 
neuronal activation in the knockouts; for example as seen in Baraboi et al. 
where higher doses of Exendin-4 injected resulted in increased responses of 
c-fos mRNA and physiological parameters (Baraboi et al., 2011). Therefore, 
to investigate this further the c-fos response to Exendin-4 was examined 
specifically in XLαs-expressing neurones in wildtype mice.  
The only region with any number of c-fos responsive XLαs neurones was the 
AP (Figure 6.5), although a couple of XLαs-positive neurones in the mNTS 
were also positive for c-fos (Figure 6.6). This suggests that XLαs might play 
a role in integration of the signal from Exendin-4, especially due to 
expression in the AP which is a circumventricular organ and can respond 
directly to circulating factors. However, in the more anterior NTS regions 
where XLαs expression is widespread, there were few activated neurones, 
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and no c-fos positive XLαs neurones (Figure 6.7), which would suggest that 
XLαs has little or no role to play in integration of vagal inputs via the NTS.  
However, this wouldn’t discount a role of XLαs-expressing neurones in 
mediating inhibition of the parasympathetic neurones, which is a possible 
mechanism of cardiovascular control by Exendin-4 (Griffioen et al., 2011), as 
neuronal inhibition doesn’t stimulate a c-fos response (Dampney & Horiuchi, 
2003).  
The most interesting result was in the PVN, where XLαs is expressed around 
the periphery of the nucleus, and all the c-fos positive neurones were found 
in a distinct population in the centre of the PVN (Figure 6.8). This shows 
clear separation of the XLαs-positive PVN neurones from those that become 
activated in response to Exendin-4, which suggests that XLαs might play a 
secondary role in the signalling pathway. For example, there are known to be 
populations of GABAergic neurones in the PVN which supply inhibitory input 
to spinally-projecting SNS control neurones (for a review see (Nunn et al., 
2011)).  
The lack of c-fos responses in XLαs-expressing neurones was also seen in 
the amygdala, where there was no overlap between XLαs-positive and c-fos 
responsive neurones (Figure 6.9). This suggests that XLαs-expressing 
neurones do not signal directly in a response pathway to activation of GLP-
1R, but are instead found in a different pathway and affect downstream 
signalling independently.  
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7 Identification of a clone for 
generating a conditional Gnasxl 
knockout mouse  
7.1 Introduction 
A useful biological tool to study gene function is the generation of knockout 
mice. However, it has limitations, including potential early lethality for critical 
genes. This technology has been improved through the use of conditional 
targeting approaches, which typically involves the addition of flanking 
sequences to the region of interest that can then be acted upon by a 
recombinase to permanently remove the intervening DNA. A classic example 
is the cre-loxp recombination system.  
7.1.1 cre-loxP mediated recombination 
cre recombinase acts upon a pair of loxp recognition sites, which are 20-bp 
sequences that are recognised by the enzyme and undergo recombination 
(Lewandoski, 2001). This allows the production of conditionally targeted mice 
that have loxp sites recombinantly targeted to a gene or genetic region of 
interest; a conditionally targeted mouse should be functionally wildtype, but 
can be crossed with a mouse expressing cre under the control of a promoter 
of interest. This will then cause the DNA flanked by loxp sites to be 
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permanently cleaved out, but solely in those cells that express cre enzyme  
(Lewandoski, 2001).  
However, there are complications with this technique, for example cre-
expressing mice can have ectopic or “leaky” expression of cre enzyme, 
which would cause undesired recombination (Lewandoski, 2001). 
Additionally, as the target is permanently cleaved from the DNA, cre 
expression during embryonic development can result in widespread gene 
deletion in the adult. 
The benefits of conditional targeting technology with respect to studying 
function of Gnasxl are abundant. Firstly, it will be possible to specifically 
delete Gnasxl in the brain, but not in peripheral tissues, providing final 
confirmation that the Gnasxlm+p- knockout phenotype is caused by central 
effects; this would be done using a nestin-cre mouse line (Tronche et al., 
1999). Secondly, it will be possible to knock out Gnasxl in particular 
populations of neurones, which would go a long way to narrowing down the 
site of action, and mechanism, of XLαs function. Targets of particular interest 
would be GABAergic neurones (using VGAT-cre) (Vong et al., 2011) and 
PVN neurones (using Sim1-cre) (Balthasar et al., 2005). The possibilities are 
diverse and ever-increasing as more cre lines are produced.  
An additional benefit of conditional gene targeting technology is that it is 
possible to add a marker to the conditional allele that becomes expressed 
upon cre recombination (Livet et al., 2007). Of particular interest is one of the 
wide range of fluorescent proteins that are currently available, as these will 
identify the neurones in brain slices, allowing patch clamping of only the 
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neurones of interest (Vong et al., 2011). In addition, there are very good 
immunohistochemistry antibodies available against fluorescent proteins  
(Llewellyn-Smith et al.).  
7.1.2 Conditional targeting of Gnasxl 
In the case of Gnasxl, there is no possibility of a simple conditional targeting 
approach due to the highly complex nature of the regulation of Gnasxl  
expression, in particular the imprinting control region that is found in the early 
5’ region of Gnasxl and further upstream (Williamson et al., 2006). It would 
therefore be essential to come up with a targeting strategy that doesn’t affec t 
this upstream control region. One such strategy is to use a conditional gene 
trap approach, which was placed downstream of Gnasxl exon 1 (Krechowec 
et al., 2012).  
The conditional gene trap approach uses 2 pairs of mutually incompatible 
loxp sites (Lee & Saito, 1998), which causes a permanent inversion of the 
intervening DNA sequence upon cre recombination (Krechowec et al., 2012). 
It is called a gene trap because inversion of the intervening DNA activates a 
previously silent splice acceptor site that “captures” splicing from exon 1 of 
Gnasxl and is followed by a stop codon, resulting in premature termination of 
the protein.  
The conditional Gnasxl gene-trap was unexpectedly found to cause an 
approximate 90 % knock-down of Gnasxl, resulting in a Gnasxl hypomorph 
that showed the characteristic knockout phenotype even in the “wildtype” un-
recombined state (Krechowec et al., 2012). This made it useless for 
investigating Gnasxl function, but the genetrap was constructed using a lacz 
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marker, which can be used to produce robust staining (XGal staining), and 
was used to give additional insight into the changing neonatal-to-adult 
phenotype of Gnasxl (Krechowec et al., 2012). The knock-down effects to 
Gnasxl were found to be caused by the location of the inserted gene-trap (ie. 
in the A20 exon), which was known to be a rarely used splice acceptor site 
(Hayward et al., 1998), but has since been shown to include enhancer 
functions for Gnasxl expression (unpublished data from other lab members).  
7.1.3 Aims 
Conditional targeting of Gnasxl is still of interest, so a new targeting 
approach was employed, where the targeting cassette was inserted much 
further downstream in the intron. Additionally the lacz marker was replaced 
with a red fluorescent protein, which would be of use for patch clamping 
experiments. The construct was transfected into mouse embryonic stem (ES) 
cells, and the aim of this chapter is to identify a correctly targeted ES cell 
clone using Southern blotting.  
7.2 Methods 
1152 ES cell colonies (ie. twelve 96-well plates) were placed in tail lysis 
buffer at 55 °C for 12 hours; DNA was extracted using isopropanol 
precipitation and ethanol cleaning, then dissolved in 50 µl TE. Once the DNA 
was fully dissolved, 20 µl was used in a Bgl II restriction enzyme digest 
overnight at 37 °C. Samples were run on a 0.8 % agarose gel for 18 hours at 
40 V to give good separation of large (ie. more than 15 kb) DNA fragments. 
DNA was then transferred to a Hybond N+ membrane (GE Healthcare) by 
semi-dry blotting for 48 hours. Details of the probes used are given below 
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(Table 7.1); details of probe hybridisation and colour development are given 
in Chapter 2. 
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Table 7.1. Probes used for Southern blotting.  
The primers used for each probe used in Southern blotting, as well as the 
size and target of each probe.  
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7.3 Results 
1152 ES cell colonies were screened by Southern blot for correct insertion of 
the targeting cassette; two positive hits were then confirmed as being 
correctly targeted by blotting after restriction digest across the 5’ and 3’ 
homologous arms. 
7.3.1 Screening ES cells colonies 
7.3.1.1 Selecting restriction enzymes 
Using the plasmid editing program ApE, the region of cassette insertion was 
screened for restriction enzymes that would cut genomic DNA outside of the 
homologous arms, but not within the arms or the insert itself. Bgl II was found 
to fit these criteria, producing a fragment of approximately 15.3 kb in the 
wildtype genome and 18.7 kb in the correctly targeted genome (Figure 7.1A).  
7.3.1.2 Designing probes 
Two probes were produced by Dig synth PCR, as described previously, 
using a plasmid containing the appropriate genomic DNA and the XL 5’ 
probe primers (Table 7.1). Full details of the probes used are in Table 7.1 
showing the size, target and primers used for each probe. The XL 5’ probes 
were designed to bind between the Bgl II restriction site and the 5’ 
homologous arm (Figure 7.1A).  
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7.3.1.3 Results from Southern blot screen 
Of the 1152 clones screened, 2 positive hits were found (Figure 7.1B), both 
of which showed a second band at 18 kb that was not seen in any of the 
other samples.  
  
Chapter 7: Southern blot screening for a conditional knockout 
165 
 
 
Figure 7.1. Southern blot screen for correctly targeted ES cell clones.  
(A) Schematic showing restriction sites for Bgl II (green) in WT (top) and 
correctly targeted (bottom) genomic DNA. The probes used are shown in 
purple and orange, and the size of the visualised fragments is shown.  
(B) Two positive hits were found in the screen: clones 1DC1 (i) and 7AC4 (ii), 
which are shown alongside the neighbouring, negative, samples.  
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7.3.2 Confirming hits from Southern blot screen 
7.3.2.1 Selecting restriction enzymes 
Using ApE, two restriction enzymes were found that would cut in one of the 
homologous arms on one side, and outside the homologous arms on the 
other side: Bgl I and Spe I, as shown in Figure 7.2A.  
7.3.2.2 Designing probes 
Two probes were produced by Dig synth PCR against the neomycin 
resistance gene, using an appropriate plasmid as target DNA. Full details of 
the probes used are in Table 7.1 showing the size, target and primers used 
for each probe. 
7.3.2.3 Results from confirmatory Southern blot 
Both of the positive hits from the ES cell screen were tested for correct 
insertion. Each sample was digested with Spe I and Bgl I in separate 
reactions. Each digest had a band in the expected position to confirm correct 
targeting (Figure 7.2B).  
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Figure 7.2. Confirmatory Southern blot of identified ES cell clones.  
(A) Schematic showing restriction sites for Bgl I (green) and Spe I (purple) of 
a correctly targeted clone, showing a simplified targeting construct and 
surrounding genomic DNA. The probes used are shown in orange and red, 
and the size of the fragments, provided correct targeting, are shown. The 
construct contains an inverted splice acceptor (SA) before a red fluorescent 
protein (tdTomato), which are flanked by double loxp sites, which serve to 
invert the intervening DNA upon cre recombination, see Krechowec et al. for 
further information (Krechowec et al., 2012). Loxp sites and flp sites have 
been omitted for clarity.  
(B) (i) Clone 1DC1 and (ii) clone 7AC4 both had bands at the correct 
distance when digested with each Bgl I and Spe I.  
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7.4 Discussion 
The aim of this chapter was to identify a correctly targeted ES cell clone that 
could be used to produce a conditional Gnasxl knockout mouse. This was 
done by Southern blot screening, and two clones were discovered (Figure 
7.1). Confirmation was provided by an additional Southern blot using 
restriction enzymes chosen to test correct location of each homologous arm 
with respect to the surrounding genomic DNA (Figure 7.2).  
The next step will be to culture the successful clones to produce colonies 
that could then be injected into blastocysts, which would be implanted into 
pseudopregnant females, and hopefully the modified genetic material be 
transmitted by chimaeras born via the gametes to produce a stable mouse 
line.  
Further experiments would include conditionally knocking out Gnasxl in 
specific populations of neurones using cre-driver lines, for example in PVN 
neurones (Balthasar et al., 2005). Additionally, due to the incorporation of a 
fluorescent protein marker in the gene trap, it will be possible to perform 
patch clamp experiments targeting those Gnasxl neurones that have been 
inactivated. Overall, this mouse line, when generated, will provide abundant 
exciting avenues for further experimentation. 
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8 Discussion 
8.1 Autonomic control in mice lacking XLαs 
A previous study suggested that Gnasxl knockout mice have a global 
increase in SNS activity (Xie et al., 2006). Here it was shown that 
anaesthetised knockouts had elevated blood pressure (Figure 3.2), 
confirmed to be caused by increased SNS stimulation by injection of the 
sympatholytic reserpine (Figure 3.3). This was supported by elevated heart 
rate in conscious knockouts (Figure 3.5), and a significant heart rate 
response to reserpine (Figure 3.6). Interestingly, the knockouts also had a 
significant response to the parasympatholytic atropine (Figure 3.7), 
suggesting paradoxically that the knockouts had both increased SNS and 
PNS stimulation of the cardiovascular system. 
A recent study by Gayen et al. investigated the role of the SNS in the 
hypertensive phenotype of the Chromogranin A knockout mouse (Gayen et 
al., 2009). Mice lacking the secretory protein Chromogranin A have elevated 
levels of circulating catecholamines in plasma; this correlates to the elevated 
levels of excreted catecholamines seen in mice lacking XLαs (Xie et al., 
2006). Gayen et al. showed that the Chromogranin A knockout had elevated 
blood pressure and heart rate in conscious freely-moving conditions, but this 
difference was lost under anaesthesia. The authors suggest that this effect 
was caused by loss of the normally elevated SNS activity in the knockouts.  
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This situation could be recapitulated in the Gnasxl knockouts. The elevated 
blood pressure in knockouts could have been detected only because of the 
anaesthetic used and the dose-matching used in the cannulation experiment. 
Gayen et al. also investigated the heart rate changes to SNS and PNS 
inhibition of the cardiovascular system, by injection of propranolol and 
atropine, respectively. The Chromogranin A knockouts were found to be 
hypersensitive compared to wildtypes in response to both, similar to the 
effects seen in XLαs knockouts. Gayen et al. suggested that this 
hypersensitivity might be caused either by diminished baroreceptor function, 
or by heightened activity of both the SNS and PNS.  
Cardiovascular control in Gnasxl knockouts was further investigated by HRV 
analysis using FFTs, which were validated in wildtype mice to give valid 
frequency ranges for HF power to indicate PNS activity and LF/HF ratio to 
indicate SNS activity (Figure 4.4). Following injection in conscious mice, 
Gnasxl knockouts had a greater LF/HF response to reserpine than wildtypes 
(Figure 4.7), but a similar HF power response to atropine (Figure 4.8). This 
implied that the increased blood pressure and heart rate in Gnasxl knockouts 
was caused by elevated SNS stimulation of the cardiovascular system; 
however, this does not discount other underlying mechanisms, for example 
changes to baroreflex function or the renin-angiotensin system.  
Additionally, there was no change to PNS stimulation, suggesting that the 
heart rate response to atropine may have been a result of heightened SNS 
stimulation. However, baroreceptor function was not investigated; as 
suggested by Gayen et al. diminished baroreceptor function might give the 
cardiovascular responses seen. 
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8.2 Neuronal signalling via XLαs  
The possible signalling pathways involved in XLαs control of the 
cardiovascular system was investigated by injection of melanocortin and 
GLP-1R agonists. Knockouts had a hypersensitive heart rate response both 
to centrally injected MTII in anaesthetised mice (Figure 5.2) and peripherally 
injected Exendin-4 in conscious mice (Figure 5.6). Further analysis of HRV 
indicated that Exendin-4 caused a highly significant decrease in HF power in 
both wildtypes and knockouts (Figure 5.8), suggesting the hypersensitive 
heart rate response may be caused in a similar way to the response to 
atropine. For a summary of the physiological parameters and responses in 
Gnasxl knockouts measured in this study, see Table 8.1. 
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Table 8.1. Summary of physiological data. 
Basal physiological parameters and responses to treatment in adult Gnasxl  
knockouts and wildtype siblings. 
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The earlier part of this study showing elevated SNS stimulation of the 
cardiovascular system in Gnasxl knockouts was interesting as it confirmed a 
previous hypothesis that the mice have a systemic increase in SNS activity, 
as well as providing further evidence of the opposite phenotypes between 
mice lacking Gsα and those lacking XLαs. The opposing phenotypes of 
Gnasxl and Gnas knockouts were further supported by the hypersensitive 
heart rate response of Gnasxl to the MC4R agonist MTII, as mice lacking 
Gsα are resistant to MTII. Furthermore, the hypersensitive heart rate 
response to Exendin-4 suggests that the hypersensitivity to SNS-stimulating 
neuropeptides may be a common phenotype in Gnasxl knockouts.  
Neuronal signalling responses to Exendin-4 were investigated by 
immunohistochemistry staining for c-fos, which showed similar responses 
between wildtypes and knockouts in a number of brain regions involved in 
SNS control of the cardiovascular system (Figures 6.2-4). Interestingly, 
although XLαs was expressed in a number of the brain regions that 
responded to Exendin-4, the only response in XLαs positive neurones was in 
NTS regions with few XLαs neurones and in the AP. Any c-fos response in 
XLαs-expressing neurones was conspicuously absent in the hypothalamus, 
specifically in the PVN and the amygdala. These data suggest that XLαs 
might function via a secondary effect to increase sensitivity of downstream 
signalling pathways.  
A possible mechanism of XLαs action is shown in Figure 8.1, which proposes 
that XLαs is expressed in neurones secondary to the main action of GLP-1R 
(or other neuropeptide) pathways. Of particular interest is the expression of 
XLαs in a population of PVN neurones adjacent to many Exendin-4-
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responsive neurones. This suggests that XLαs might provide tonic inhibitory 
input to downstream SNS control neurones, for example via GABA. A 
previous study showing the ability of XLαs to continue signalling at the 
plasma membrane longer than Gsα might even suggest a mechanism for 
how these neurones remain tonically active (Liu et al., 2011). Loss of XLαs 
would therefore result in a decrease in tonic GABA release, resulting in 
hyperactive and hypersensitive downstream SNS control neurones. 
The hypersensitivity of Gnasxl knockouts to agonists for GLP-1R and MC4R 
suggests a second mechanism in which Gnasxl acts in inhibitory neurones to 
dampen SNS outflow, separate from the main GLP-1 or melanocortin 
signalling pathways (Figure 8.2). In this scheme, loss of XLαs would result in 
constitutively elevated SNS outflow, as well as increasing sensiti vity to GLP-
1R or MC4R agonists, but only by indirect means. 
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Figure 8.1. Scheme depicting how XLαs might signal in response to 
Exendin-4: part I. 
In this scheme, XLαs is expressed in a PVN neurone that is separate to the 
main GLP-1R signalling pathway. The XLαs-expressing neurone provides a 
separate input to the same downstream SNS control neurones, possibly by 
constitutive inhibitory activity. In this way, loss of XLαs could result in 
chronically elevated SNS activity, as well as a hypersensitive response to 
Exendin-4 without resulting in activation of XLαs neurones.  
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Figure 8.2. Scheme depicting how XLαs might signal in response to 
Exendin-4: part II. 
In this scheme, XLαs is expressed in a pathway that inhibits SNS outflow, but 
is completely separate from the pathway that mediates the response to 
Exendin-4. The hypersensitivity to Exendin-4 in Gnasxl knockouts is caused 
by the dominant effect of heightened SNS outflow after inhibition of the PNS 
by Exendin-4. 
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8.3 Speculative discussion 
8.3.1 Future work 
This study poses many interesting questions about the mechanism by which 
XLαs functions. Although it suggests a secondary, or at least inhibitory, 
mechanism of some kind, there is still much that remains unknown. An 
interesting follow-up experiment would be to perform the IF co-localisation of 
c-fos response to Exendin-4 in Gnasxl knockouts with a marker for XLαs 
neurones. In this way, it would be possible to determine whether loss of XLαs 
changes the signalling behaviour of neurones that normally express it.  This 
would be possible using a conditional knockout, similar to that described in 
chapter 7, which expresses a marker in neurones that have had XLαs 
knocked out. 
There are a number of directions in which this work could be further 
investigated. Firstly would be the use of conditional knockouts for Gnasxl, 
which was the driving force behind Chapter 7. For example, it would be very 
interesting to knock out XLαs in GABAergic neurones, because the data 
shown here suggest that XLαs functions in an inhibitory manner. There are 
also strong indications that GABA signalling plays a major role in control of 
energy balance and in SNS control (Vong et al., 2011). 
Secondly would be patch clamp electrophysiology. Again, an interesting 
course of action would be to investigate GABAergic signalling, for example, 
GABAergic control of spinally-projecting neurones of the PVN. This could be 
done by recording electrophysiologically from retrogradely-labelled 
sympathetic-projecting neurones of the PVN. The other main 
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electrophysiology route would be using mouse models with GFP-labelled 
neurone populations. For example, using mice with fluorescently labelled 
GABA-ergic neurones, as these are likely to behave differently in mice 
lacking XLαs. Ideally, one would want to record from identi fied XLαs 
neurones, which would require the generation of a knockin mouse line 
expressing fluorescent proteins under the control of the Gnasxl promoter. 
However, this would enable a researcher to test what XLαs-expressing 
neurones responds to (eg. neuropeptides such as GLP-1 or metabolic 
signals such as glucose). 
Thirdly, it would be interesting to use in situ hybridisation to investigate 
orphan GPCRs that might couple to XLαs. For example, the orphan receptor 
Gpr101 has been shown to have an expression pattern almost identical to 
XLαs, and is likely to influence cAMP signalling (Bates et al., 2006). Provided 
a likely GPCR could be identified, this could be followed up by a knockout 
mouse specific to that receptor, and further studies involving double 
knockouts or targeted knockouts using a Gnasxl-cre line.  
An interesting feature of the Gsα mutations is the dose-dependent aspect of 
the phenotype. Paternally inherited Gnas mutations cause AHO in human 
patients, and a similar phenotype in mice, even though there is heterozygous 
expression of Gsα. Additionally, the recent paper by Fernandez-Rebollo et al. 
suggests that there is a dose-dependent effect of XLαs (Fernandez-Rebollo 
et al., 2012). It would be interesting to investigate the effect of XLαs over -
expression in adults, to see if this recapitulates the XLαs knockout phenotype 
(as suggested by the Fernandez-Rebollo paper), and whether the signalling 
effects are the same as seen in the knockouts, ie. would XLαs 
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overexpression result in elevated SNS activity and hypersensitivity to 
Exendin-4?  
8.3.2 Broader implications 
There is no direct medical relevance for this work, as there is no known 
pathology associated with mutation of XLαs in humans – although it is 
possible that the leanness and poor suckling behaviour associated with this 
mutation goes unnoticed in the clinical setting. However, due to the highly 
conserved nature of the Gnas locus, and the similarities in the effects of Gsα 
mutation between humans and mice, it seems likely that XLαs exerts effects 
in humans. This would make it an attractive drug target, as selective 
inhibition of XLαs would almost certainly results in reproducing the effects of 
the knockout, ie. to drastically increase energy expenditure and improve 
glucose tolerance, which would benefit obese patients. 
The most interesting aspect of this work is the link between XLαs and 
hypersensitivity to Exendin-4. As mentioned earlier, Exendin-4 is in clinical 
use to improve management of type 2 diabetes. If the hypersensitivity in 
response to inhibition of XLαs was also seen in humans, this might make an 
XLαs antagonist additionally effective by improving the responsiveness to 
Exendin-4. 
This work also provides the first, albeit indirect, evidence for a mechanism for 
the action of XLαs in vivo. It suggests an inhibitory role of XLαs-expressing 
neurones separate from the main pathways of metabolism and 
cardiovascular control via central neuropeptide signalling pathways. The 
expression pattern of XLαs in the PVN in the particular suggests these 
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neurones might be involved in tonic suppression of the SNS output, so an 
antagonist would result in both elevated SNS control of metabolism and 
hypersensitivity to the normal homeostatic control mechanisms.  
In summary, this work provides insight into the little-known effects of the 
signalling protein XLαs and provides a platform for exciting further avenues 
of research.  
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Publications from this work: 
1. Nunn N, Womack M, Dart C, & Barrett-Jolley R (2011) Function and 
Pharmacology of Spinally-Projecting Sympathetic Pre-Autonomic 
Neurones in the Paraventricular Nucleus of the Hypothalamus.  
Curr.Neuropharmacol. 9(2): 262-277 
2. Krechowec S, Burton K, Newlaczyl A, Nunn N, Vlatkovic N, & Plagge 
A (2012) Postnatal changes in the expression pattern of the imprinted  
signalling protein XLαs underlie the changing phenotype of deficient 
mice. PLoS ONE 7(1): e29753 
3. Nunn N, Feetham C, Plagge A, & Barrett-Jolley R (2012) Deregulated 
autonomic control causes elevated blood pressure, heart rate and 
body temperature in mice lacking the XLαs protein of the Gnas locus. 
PLoS ONE (Under Review)  
Abstracts from this work: 
1. Nunn N, Barrett-Jolley R, & Plagge A (2009) Brown adipose tissue 
development and cardiovascular parameters in Gnasxl knock-out 
mice. Proceedings of the British Pharmacological Society 7(3): 49P 
2. Burton K, Nunn N, Krechowec S, Barrett-Jolley R & Plagge A (2010) 
Hypothalamic expression pattern and molecular and physiological 
markers indicate elevated sympathetic stimulation of metabolism in 
XLαs-deficient mice. Co-author and co-presenter of a poster 
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imprinted signalling protein XLαs in mice results in increased 
sympathetic stimulation of the cardiovascular system. Oral 
presentation to 22nd Mammalian Genetics and Development 
Workshop. Published in Genetical Research 94(1): 51-52 
4. Nunn N, Feetham CH, Plagge A, & Barrett-Jolley R (2011) 
Investigation of cardiovascular parameters as indicators of 
sympathetic activity in lean and hypermetabolic gnasxl knock -out 
mice. Proceedings of the Physiol Society 23: PC27 
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Hypermetabolic Gnasxl knock-out mice have increased sympathetic 
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